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Abbreviations 
      
APC antigen presenting cell 
ATCC American type culture collection 
BSA bovine serum albumine 
CD cluster of differentiation 
CTL cytotoxic T cell 
cDNA complementary DNA 
cpm counts per minute 
DC dendritic cell 
EBI3 EBV-induced gene 3 
EBV Epstein Barr Virus 
FITC fluorescin-5-isothiocyanate 
Foxp3 forkhead box P3 
GM-CSF granulocyte-macrophage colony stimulating factor 
HRP horse radish peroxidase 
HRV Human Rhinovirus 
ICAM intercellular adhesion molecule 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
Iono ionomycin 
JAK Janus kinase 
kDa kilo-Dalton 
LDL Low density lipoprotein 
mAb monoclonal antibody 
MHC major histocompatibility complex 
MLR mixed leukocyte reaction 
MV Mean value 
MW molecular weight 
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OG oregon green 
PBMNC peripheral blood mononuclear cells 
PCR Polymerase chain reaction 
PE phycoerythrin 
PMA phorbol myristate acetate 
SD standard deviation 
SDS-PAGE 
sodiumdodecylsulfate polyacrylamide  
gelelectrophoresis 
SN supernatant 
STAT signal transducer and activator of transcription 
TCID Tissue culture infectious dose 
TCR T cell receptor 
TGF-ß transforming growth factor beta 
Th T helper cell 
TLR Toll-like receptor 
TNF tumor necrosis factor 
Treg regulatory T cell 
qPCR quantitative PCR 
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Summary 
 
IL-35 is a heterodimer of EBV-induced gene 3 (EBI3) and of the p35 subunit of 
IL-12, which has recently been identified as an inhibitory cytokine produced by 
natural regulatory T cells in mice, but not in humans. Here we demonstrate that 
dendritic cells (DCs) activated by human rhinoviruses (R-DCs) induce IL-35 
production and release in human T cells. 
The first finding of this thesis was that R-DCs induce a suppressor function in 
cocultured T cells. This suppressor function was induced in CD4+ and CD8+ T 
cells derived from human peripheral blood but not in naïve T cells from cord 
blood. It was further observed that the cell culture supernatant (SN) of 
peripheral blood T cells (both CD4+ and CD8+) cocultured with R-DCs had an 
inhibitory effect on T cells. Therefore the inhibition was not cell-cell contact 
dependent and we focused on soluble factors. When we blocked the classical 
inhibitory cytokines including IL-10, TGF-ß or IFN-α with antibodies against the 
respective factors, the SN was still inhibitory. Therefore the inhibition was not 
caused by the release of these cytokines. Via qPCR, flow cytometry and 
immuno-precipitation it was shown that, R-DC-induced regulatory T cells 
produced and released IL-35. When we blocked the inhibitory SN with Abs 
against either subunit of IL-35, the inhibitory effect was gone. Hence IL-35 was 
responsible for the inhibitory effect of the SN. In addition, the p35 depleted SN 
was no longer inhibitory. The induction of IL-35 producing T cells (IL-35+ 
regulatory T cells) by R-DCs did not correlate with an increased Foxp3 
expression, indicating that R-DCs do not induce classical regulatory T cells.  
In order to determine which structures on R-DCs influence the generation of IL-
35+ regulatory T cells, blocking antibodies against R-DCs inhibitory surface 
molecules B7-H1 (CD274) and sialoadhesin (CD169) were added. Most 
importantly we observed that, when we blocked B7-H1 and sialoadhesin on the 
R-DC side with specific mAb against both receptors, the induction of IL-35 was 
prevented. Thus, the combinatorial signal delivered by R-DCs to T cells via B7-
H1 and sialoadhesin is crucial for the induction of human IL-35+ regulatory T 
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cells, defining a new route of T-cell instruction.  
These results demonstrate a novel pathway and its components for the 
induction of immune-inhibitory T cells and show for the first time that IL-35 is 
immune-inhibitory in humans. The findings of this thesis contribute to a better 
understanding of immune evasion strategies of human rhinoviruses (HRV) the 
major cause of the common cold. 
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Zusammenfassung 
 
IL-35 ist ein Heterodimer, bestehend aus EBV-induziertem Gen 3 (EBI3) und 
p35, einer der beiden Untereinheiten von IL-12. Dieses Zytokin wurde kürzlich 
als inhibitorisch beschrieben und wird von den natürlich regulatorischen T-
Zellen der Maus, jedoch nicht von denen des Menschen produziert. In dieser 
Dissertation wird gezeigt, dass Dendritische Zellen, die mit humanem 
Rhinovirus (HRV) aktiviert sind (R-DZs), die Produktion und Freisetzung von IL-
35 in humanen T-Zellen induzieren.  
Werden T-Zellen mit R-DZs kokultiviert, wird in den T-Zellen eine 
supprimierende Funktion auf andere T-Zellen beobachtet. Sowohl in CD4+ als 
auch in CD8+ T-Zellen des peripheren Blutes, jedoch nicht in aus humanem 
Nabelschnurblut gewonnenen naiven T-Zellen, konnte diese inhibierende 
Funktion durch R-DZs induziert werden. Weiters wird gezeigt, dass der 
Zellkulturüberstand von T-Zellen des peripheren Blutes (CD4+ als auch CD8+ T-
Zellen), die mit R-DZs kokultiviert wurden, inhibierend ist. Diese Beobachtung 
lässt den Schluss zu, dass die Effekte nicht durch Zell-Zell-Kontakt, sondern 
durch lösliche Faktoren hervorgerufen wurden. Die klassischen immun-
inhibitorischen Zytokine IL-10, TGF-ß oder IFN-α waren jedoch nicht für diesen 
Effekt verantwortlich, da ein Blockieren dieser Faktoren durch Antikörper nichts 
an der hemmenden Eigenschaft des Zellkulturüberstandes änderte. Wir 
konnten mittels qPCR, Durchflusszytometrie und Immun-Präzipitation zeigen, 
dass IL-35 von mit R-DZs kokultivierten T-Zellen produziert und freigesetzt wird. 
Ein Blockieren der beiden IL-35 Untereinheiten (EBI3 und p35) mit Antikörpern 
gegen diese Strukturen konnte die Hemmung aufheben. Damit wird gezeigt, 
dass IL-35 für die inhibitorische Eigenschaft des Zellkulturüberstandes 
verantwortlich ist. Depletion von IL-35 aus dem zuvor hemmenden 
Zellkulturüberstand führte ebenso zum Verlust dieser Funktion. Die Induktion 
dieser IL-35 produzierenden T-Zellen (IL-35+ T-Zellen) durch R-DZs zeigte 
keine Korrelation mit erhöhter Foxp3 Expression. Dies könnte ein Hinweis 
darauf sein, dass keine klassischen regulatorischen T-Zellen induziert werden. 
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Durch das Hochregulieren der inhibitorischen Oberflächenmoleküle B7-H1 
(CD274) und Sialoadhesin (CD169) sind R-DZs schlechte T-Zell-Stimulatoren. 
Als wir diese beiden Oberflächenmoleküle mit Antikörpern, die gegen diese 
Strukturen gerichtet sind, blockierten, verhinderten wir die Induktion von IL-35. 
Wir schließen daraus, dass ein kombinatorisches Signal der R-DZs, vermittelt 
durch B7-H1 und Sialoadhesin, an die T-Zellen für die Induktion der IL-35+ T-
Zellen verantwortlich ist.  
Unsere Ergebnisse beschreiben einen neuen Weg und seine Bausteine in der 
Induktion von immun-inhibitorischen T-Zellen. IL-35 wird zum ersten Mal als 
inhibitorisches Zytokin im Humansystem nachgewiesen. Weiters bekommen wir 
Einblick in die Strategien von HRV, dem Haupterreger des Schnupfens, dem 
Immunsystem zu entgehen. 
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Introduction 
 
One of the main functions of the immune system is the control of infection [1]. 
The contact with a pathogen requires a strong and efficient response of the 
immune system to prevent harm for the organism. Yet, potent immune 
responses can be accompanied by severe side-effects with immune-pathology 
as a final result. Thus, anti-pathogen responses need to be controlled 
adequately. There is increasing evidence that suppressor or regulatory T cells 
(Tregs) are critically involved in the control of immunity to infection. In turn, 
recent studies suggest that pathogens actively provoke the generation of Tregs 
thereby harnessing these regulatory cells to evade the immune system.  
 
T Lymphocytes (T cells) 
 
T cells are main effectors in the adaptive immune response. Furthermore they 
serve as crucial effector cells through antigen specific cytotoxic activity and the 
production of soluble mediators (cytokines). The T cells antigen receptors are 
membrane molecules distinct from but structurally related to antibodies. T cells 
have a restricted specificity for antigens; they recognize mainly peptide antigens 
attached to host proteins that are encoded by genes in the MHC and that are 
expressed on the surface of other cells [2]. 
T cells consist of functionally distinct populations, the best defined of which are 
helper T cells, which express the CD4 co-receptor on their surface and are 
restricted to MHC class II, and cytotoxic T cells (CTLs), which are CD8 positive 
and recognize MHC class I. In response to antigenic stimulation helper T cells 
secrete proteins called cytokines. Their function is to stimulate the proliferation 
and differentiation of the T cells as well as of other cells, including B cells, 
macrophages, and other leukocytes. CTLs kill cells that present foreign 
antigens, such as cells infected by viruses or other intracellular microbes.  
The initiation and development of adaptive immune responses requires 
antigens to be captured and displayed to specific T cells. The cells that serve 
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this role are called antigen presenting cells (APCs). The most highly specialized 
APCs are dendritic cells (DC). DCs capture antigens that enter from the 
external environment, transport these antigens to lymphoid organs, and present 
the antigens to naïve T cells to initiate immune responses. APCs also include 
mononuclear phagocytes and B cells, but also mesenchymal cells such as 
fibroblasts. All of these cells are capable of expressing MHC class II molecules 
and co-stimulatory molecules [2].  
 
T cell subsets 
 
CD4+ T cells – T helper cells 
 
Helper T cells usually express CD4 and recognize peptides displayed by MHC 
class II molecules. In 1986 Mosmann and Coffman reported that distinct CD4 T 
cell subtypes, termed T helper type 1 (Th1) and T helper type 2 (Th2) T cells, 
could be distinguished on the basis of cytokine secretion and function [3]. The 
Th1/Th2 model provided a useful and relatively simple explanation for our 
understanding of the mechanisms of immunity to infection. The original 
hypothesis was that interferon-gamma (IFN-gamma) secreting CD4 cells 
mediated protective immunity to intracellular pathogens. In contrast, CD4 T cells 
that secreted IL-4, IL-5, IL-10 and IL-13 were considered to be the main helper 
T cells providing help for B cell production of antibody and mediated protective 
immunity to extracellular pathogens. Over the years the picture became more 
complicated and also more subsets of T helper cells arised.  
 
Th1 and Th2 
After being activated, naive CD4+ T cells differentiate into functional subsets 
called Th1 and Th2 cells, based on their production of IFN-gamma and IL-4, 
respectively [4]. Th1 and Th2 subsets develop from the same precursors, and 
the pattern of differentiation is determined by stimuli present early during 
immune response [2]. The decision to develop into Th1 or Th2 effectors 
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appears to be dependent on cytokines these naïve T cells are exposed to 
during primary activation. IL-12, produced by activated macrophages and DCs, 
is considered the principal Th1-inducing cytokine, while IL-4 appears to be the 
important cytokine for induction of a Th2 response [5]. IL-12 enhances 
expression of the transcription factor T-bet and STAT-4 and promotes 
development of Th1 cells, whereas IL-4 enhances expression of GATA-3 and 
STAT-6 and promotes development of Th2 cells. Although the differentiation 
and function of these Th subsets has been intensively studied, little is known 
about the contribution of cell surface receptors to these differentiation events, 
other than those for soluble cytokines, such as IL-12 or IL-4 [6]. The Notch 
signaling pathway is an evolutionarily highly conserved mechanism for cell-to-
cell communication, important for many types of cell fate determinations [7]. 
APCs use the Notch pathway to instruct T cell differentiation. Strikingly, of the 
two Notch ligand families, Delta1 induces Th1, while Jagged induces the 
alternate Th2 fate. Expression of these different Notch ligands on APC is 
induced by Th1- or Th2-promoting stimuli [8]. Delta1 interaction with Notch3 on 
CD4+ T cells transduces signals, promoting development toward the Th1 
phenotype [6]. 
A given Th cell subset is characterized by its cytokine-secretion profile which is 
intimately associated to the effector functions. Th1 cells mediate cellular 
immunity against intracellular bacteria and viruses by secreting cytokines such 
as IFN-gamma and tumor necrosis factor-α (TNF-α). Th2 cells regulate humoral 
immunity and immunity against extracellular parasites by producing IL-4, IL-5 
and IL-13 [9]. Th1 cells can mediate macrophage activation and delayed type 
hypersensitivity, which are collectively termed cell-mediated immune responses 
[10]. Whereas Th2 T cells promote secretion of IgG1 and IgE by B cells and 
promote immediate-type hypersensitivity reactions, collectively termed humoral 
immunity [11].  
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Th17, Th9 and Th22 
The Th17 cells, are defined via their ability to produce IL-17 and develope via 
cytokine signals distinct from, and antagonized by, products of the Th1 and Th2 
lineages [12]. Th17 cells are a distinct linage from Th1 or Th2 cells [13]. Th17 
cells produce IL-17A, IL-17F, and IL-22 and play important roles in the 
clearance of extracellular bacteria and fungi, especially at mucosal surfaces. 
Th17 cell differentiation requires retinoidrelated orphan receptor (ROR-γt). This 
transcription factor is induced by TGF-ß in combination with the 
proinflammatory cytokines IL-6, IL-21 and IL-23, all of which activate STAT-3. T-
bet and GATA3, which are involved in the development of Th1 and Th2 cells, 
inhibit the differentiation of Th17 cells.  
The cytokine IL-9 has largely been regarded as a Th2 cytokine that makes 
multifocal contributions to allergic disease. Recent data suggest that under 
certain conditions a distinct population of IL-9-producing 'Th9' helper T cells can 
arise. This new subset of the T helper population is different from Th2 and 
produces IL-9 in large quantities. TGF-ß ‘reprograms’ the differentiation of Th2 
cells and promotes this subset [14, 15]. 
IL-22 was described originally as a cytokine characteristic of fully differentiated 
Th17 cells [16]. Recently, a subset of human skin-homing memory T cells was 
shown to produce IL-22, but not IL-17 or IFNγ. Differentiation of IL-22 producing 
T cells, named Th22 cells, could be promoted by stimulation of naive T cells in 
the presence of IL-6 and TNF-α or by the presence of plasmacytoid DCs. The 
human Th22 cell population coexpresses the CCR6 chemokine receptor and 
the skin-homing receptors CCR4 and CCR10. This led to hypotheses that these 
cells may be important in skin homeostasis and pathology [17-19]. 
 
 
 
 
 
 
Introduction 
IL-35+ regulatory T cells                                                                                                            Maria Seyerl 
17
CD8+ T cells – Cytotoxic T cells  
 
CD8+ T cells mediate their effector functions through production of cytokines 
such as IFN-gamma and TNF-α and/or by cytolytic mechanisms. Their major 
effector function is to recognize and kill host cells infected with viruses or other 
intracellular microbes. Such responses are important in preventing or 
maintaining control against disease in a variety of intracellular infections and 
perhaps also against certain tumors [20]. CTLs usually express CD8 and 
recognize microbial peptides displayed by class I MHC molecules. CTL killing of 
infected cells involves the release of cytoplasmic granules whose contents 
include membrane pore forming proteins and enzymes. CTLs kill their cellular 
targets by either of two mechanisms that require direct contact between the 
effector and target cells. In the first pathway, cytoplasmic granule toxins - 
predominantly a membrane-disrupting protein known as perforin and a family of 
structurally related serine proteases (granzymes) with various substrate 
specificities are secreted by exocytosis. This induces apoptosis of the target 
cell. The granule-exocytosis pathway powerfully activates cell-death pathways 
that operate through the activation of apoptotic cysteine proteases (caspases), 
but it also leads to cell death in the absence of activated caspases. The second 
pathway involves the engagement and aggregation of target T cell death 
receptors, such as Fas (CD95), by their cognate ligands, such as Fas ligand 
(FasL), on the killer-cell membrane, which results in classical caspase-
dependent apoptosis [21]. 
 
T cell activation 
 
One of the central processes inducing and regulating immune function involves 
T cells establishing cell–cell contacts with APCs, such as B cells and DCs [22, 
23].T cells express a clonal antigen specific receptor, the T cell receptor (TCR). 
T cells bind to an MHC-antigen complex on an APC via TCR. In this way, the 
cell recognizes the antigen it has been designed for. The ability of naive T cells 
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to clonally expand and acquire effector functions depends on the strength of 
signals received by the TCR and by an array of co-stimulatory receptors [24]. 
The T cell recognizes both peptides associated with MHC molecules on the 
APC and also other molecules in a complex structure known as the 
immunological synapse [25]. The development and maintenance of an adaptive 
immune response is mediated by the trafficking of T cells through different 
tissues and organs and the subsequent interactions of these cells with other 
immune cells [26].  
 
T cell activation requires two signals  
For the full activation of T cells, the cells need to receive two distinct signals. 
The specificity of T cell responses is controlled by the antigen-specific TCR but 
the recognition of the antigen in form of the peptide-MHC complexes expressed 
by the APC (=SIGNAL 1) is not sufficient for optimal activation. Full T cell 
activation is generally achieved only in the presence of additional receptor 
ligand interactions so called costimulatory signals (=SIGNAL 2). In the absence 
of costimulatory signals lymphocytes fail to respond efficiently to antigenic 
stimulation and are rendered anergic. The interaction between T cells and the 
APC during antigen recognition creates a unique physical site, the 
immunological synapse, where specific ligands and costimulatory molecules 
trigger and sustain the T cell activation process [23]. This so called co-
stimulation is crucial to the development of an effective immune response.  
Co-stimulation can simply promote more efficient engagement of TCR 
molecules to enhance the initial activation. It can also provide additional signals 
to promote cell division, augment cell survival, or induce effector functions such 
as cytokine secretion or cytotoxicity in the process of T cell response [27, 28]. 
The best described costimulatory molecules on the APC side are B7.1 (CD80) 
and B7.2 (CD86), that signal is received via CD28 on the T cell side. The CD28 
molecule on T cells delivers a costimulatory signal upon engaging either of its 
ligands. There is a constantly growing number of other co-stimulatory molecules 
being described even though their role or mechanism of action is not always 
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clear.  
 
The immunological synapse 
The immunological synapse is a complex cellular structure that forms at the 
interface of a T cell and a cell that expresses the appropriate peptide–MHC 
complexes [27]. The immunological synapse consists of a central cluster of T 
cell molecules surrounded by a ring of adhesion molecules [29]. TCR 
molecules, CD2 and other molecules on the T cell side, such as CD28 and the 
peptide-MHC-complex and B7.1/B7.2 on the APC side are enriched in a central 
supramolecular activation cluster (cSMAC). This is surrounded by a peripheral 
ring (pSMAC) where molecules such as LFA-1 and CD45 are expressed [30]. 
The stable immunological synapse results from a polarized interaction between 
a T cell and an APC. It frequently lasts 30 minutes or longer and is defined by 
recruitment and segregation of cell-surface receptors and adaptor proteins at 
the cell–cell junction, and is responsible for sustained transmission of 
intracellular signals. The development of the immunological synapse comprises 
five phases:  
1. cellular scanning, contact acquisition and adhesive arrest;  
2. early immunological-synapse assembly and signalling;  
3. maturation and receptor segregation;  
4. TCR internalization; and  
5. immunological–synapse dissolution [23, 31].  
 
Progression through all of these phases requires sustained peptide–MHC–TCR 
interaction, sustained membrane-proximal signalling and an intact T cell 
cytoskeleton. Although the processes that regulate the first four phases have 
been studied in detail, the processes that control immunological-synapse 
resolution and T cell detachment are not as clear [32].  
Following the initiation of T cell activation the process of T cell response 
involves a series of complex events. After recognition of the antigen MHC 
complex on the APC, T cells commit to programmed expansion in the first few 
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hours of activation. Subsequently T cells go on to differentiate into effector cells, 
which can interact with B cells in the germinal center and migrate out of the 
lymphoid organs carrying out their effector functions in the peripheral tissue. 
Although the majority of T cells are short lived, some antigen experienced cells 
remain as long lived memory cells.  
 
Regulatory T Cells 
 
Besides soluble mediators that control T cell homeostasis and thereby 
autoimmunity there is a need for a cellular authority to regulate both the naïve 
and memory T cell pool together with possible self reactive T cell populations 
that escaped central tolerance mechanisms. These subpopulations of cells 
have been termed regulatory or suppressor T cells (Treg). Tregs are crucial 
players in the induction of peripheral tolerance to self and foreign antigens [33, 
34]. Tregs have essential roles in maintenance of immune homeostasis. They 
regulate effector T cell responses and thus prevent their potentially pathogenic 
effects through a variety of mechanisms [35]. 
The first experiments in which such cells have been suggested, even though 
these cells were CD8 positive, were done as early as 1969 [36]. The field of 
Treg was re-discovered by the observations of Sakaguchi et al. in 1995. It was 
observed that depletion of the minor population of CD4+ T cells that coexpress 
CD25, from a population of normal adult CD4+ T cells, generated a population 
of cells that induced a spectrum of autoimmune diseases when transferred to 
an immunocompromised recipient. Cotransfer of the CD25+ cells prevented the 
development of autoimmunity [37]. 
In the last decade regulatory T cell populations have been recognized as one of 
the key players in controlling T cell homeostasis, thereby maintaining the 
quantitative and qualitative dimensions of the T cell pools. Besides the 
important roles in controlling autoimmunity, evidence has also emerged that 
regulatory T cells control immune responses to pathogens like bacteria, viruses 
or fungi.  
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Today regulatory T cells can be subdivided in two main categories. First the 
naturally occurring regulatory T cells, that are generated in the thymus, namely 
CD4+CD25+ regulatory T cells [38], and secondly: the inducible regulatory T 
cells, namely Tr1, Th3 and inducible CD4+ CD25+Treg subsets, that arise in the 
periphery. [34, 39, 40]. Both share some distinct properties that make them 
different compared to naïve and memory T cells. Upon TCR engagement of 
peptide complexed to MHC II these cells become hyporesponsive and do not 
proliferate like naïve or memory T cells [33]. Furthermore regulatory T cells are 
able to suppress the proliferation of activated responder T cells in an antigen 
independent manner although their activation itself seems to depend on antigen 
specificity [35].  
Natural occurring Tregs consist of peripheral CD4+ T cells, and are 
characterized by the constitutive expression of CD25 and the transcription 
factor Foxp3 [34]. These Tregs inhibit effector T cells responses via so far 
unknown mechanism, involving cell-cell contact. Inducible Tregs develop from 
mature T cell populations under certain conditions f.i. upon stimulation with 
tolerogenic DCs or by IL-10 treatment [41, 42]. Inducible Tregs primarily act via 
soluble mediators and typically produce high levels of immune-suppressive 
cytokines (IL-10 and/or TGF-β). The suppressive function of human inducible 
Tregs seems to be Foxp3-independent [43, 44].  
Tregs not only control autoimmunity but also immunity to pathogens, this makes 
them potentially dangerous. On the one hand, in many infectious diseases, 
immune responses can result in collateral damage of host tissue. Therefore 
immune regulatory mechanisms are essential to control immuno-pathology. On 
the other hand, pathogens can exploit these regulatory mechanisms causing a 
sort of immune subversion, thereby prolonging pathogen survival and chronic 
infection of the host [45, 46].  
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Inducible regulatory T cells 
 
Virtually any responder T cell can be induced to get a regulatory phenotype. 
The factors important for this induction are so far not fully understood but it is 
clear that the cytokine milieu plays a crucial role. T cells are in general very 
plastic and even fully developed effector T cells can by “re-programmed” to 
another fate [47]. IL-10 and TGF-ß two cytokines with suppressive capacity are 
known to be produced during the late stages of an immune response. 
Furthermore cultivation of T cells in the presence of type I IFNs and these two 
cytokines induces regulatory T cells [48]. The role of tolerizing DCs is also 
under investigation. So far it is not clear whether APC to T cell contact could be 
required but DCs are prominent cytokine producers and might be indirectly 
involved in the induction of regulatory T cells. Others propose that Tregs are 
capable to induce regulatory T cells via cell to cell contact [49, 50]. Suppression 
by induced regulatory T cells is mainly mediated via soluble factors. They 
require antigen specific activation but exert their suppressive function in an 
antigen unspecific way.  
 
Type 1 regulatory T cells (Tr1)  
T regulatory type 1 (Tr1) cells are defined by their specific cytokine production 
profile. This includes the secretion of high levels of IL-10 and medium levels of 
transforming growth factor-ß (TGF-ß). Secondly they are defined by their ability 
to suppress antigen-specific effector T cell responses via a cytokine-dependent 
mechanism [48].  
In contrast to naturally occurring CD4+CD25+ Tregs, that emerge directly from 
the thymus, Tr1 cells are induced by antigen stimulation via an IL-10-dependent 
process in the periphery. The full biological characterization of Tr1 cells has 
been difficult by the lack of specific marker molecules [39]. Tr1 cells regulate 
immune responses through the secretion of the immunosuppressive cytokines 
IL-10 and TGF-ß. It is clear that Tr1 cells play a key role in regulating adaptive 
immune responses in both, mice and humans. They have a low proliferative 
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capacity when activated via the TCR which can be overcome by IL-15 [51]. 
Furthermore they suppress immunoglobulin production by B cells and the 
antigen presenting capacity of monocytes and DCs [52]. All these effects 
described can be reverted by the addition of neutralizing antibodies against IL-
10 and TGF-ß [44]. Although antigen specific Tr1 cells need to be activated via 
the TCR in order to exert their suppressive function, once activated, Tr1 cells 
can mediate bystander suppressive activity against other antigens [39]. 
Tr1 cells can be generated in vitro and in vivo upon priming of naive T cells with 
antigen in the presence of IL-10. Specialized IL-10-producing DCs, such as 
those in an immature state or those modulated by tolerogenic stimuli, play a key 
role in inducing these cells. For example, repetitive stimulation of naive cord 
blood CD4+ T cells with allogeneic immature DCs (iDCs) results in the 
differentiation of IL-10-producing Tregs that suppress T cell responses via a 
cell-contact [53]. A large body of evidence suggests that not only iDCs but also 
specialized subsets of tolerogenic DCs may prime Tr1 cells [54]. Tolerogenic 
DCs can be induced either by biological or by pharmacological agents. For 
example, DCs treated with immunomodulatory cytokines such as IL-10 [55], 
TGF-ß [56], IFN-α [57], or TNF-α [58] become tolerogenic and induce the 
differentiation of Tr1 [54]. 
 
T helper 3 cells (Th3) 
Th3 cells have been identified during the investigation of oral tolerance [59], 
which is an active process and a continuous immunologic event, driven by 
exogenous antigen that has been orally administered. It is induced in the gut-
associated lymphoid tissues including Peyer’s patches and lymph nodes. For 
the induction of Th3 cells the cytokine microenvironment is very crucial. High 
levels of IL-4, IL-10 and TGF-ß produced by naïve T cells, mucosal cells and 
APCs can induce the differentiation of Th3 cells [60]. They exert their 
suppressive function via the production of high levels of TGF-ß and medium 
levels of IL-10 [61]. Just like Tr1 cells they need antigen specific activation 
whereas suppression is antigen unspecific. 
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Adaptive Foxp3+CD4+CD25+ regulatory T cells 
This quite recently described population, the adaptive Foxp3+CD4+CD25+ 
regulatory T cells develops outside the thymus. They arise probably under 
subimmunogenic antigen presentation, during chronic inflammation, and during 
normal homeostasis of the gut. These Tregs are essential in mucosal immune 
tolerance and in the control of severe chronic allergic inflammation, and most 
likely are one of the main barriers to the eradication of tumours. The adaptive 
Foxp3+CD4+CD25+ Treg cell repertoire is drawn from naïve conventional CD4+ 
T cells, whereas naturally occurring Treg cells are selected by high-avidity 
interactions in the thymus. The full extent of differences and similarities between 
iTreg and naturally occurring Treg cells not entirely defined at the moment [40]. 
 
Naturally occurring regulatory T cells (Tregs) 
 
The last population I am going to describe is the one that received most of the 
scientific attention in the field of T cells with regulatory properties, the Tregs or 
nTregs. Tregs constitute approximately 5-10% of the peripheral naive T cell 
repertoire [62] and have emerged as the dominant T cell population governing 
peripheral self tolerance [38]. TCR stimulation is required to induce suppressor 
function which is exerted in an antigen non-specific (bystander) fashion. Tregs 
themselves are hyporesponsive upon activation via the TCR and start to 
proliferate only when exogenous IL-2 is added to the culture. Many models 
have been proposed concerning the development of Tregs which takes place in 
the thymus. Natural CD4+CD25+ Tregs are selected in the thymus and thus 
have predefined antigen specificity [62]. CD4+CD25+ Tregs are identified on the 
basis of cell surface markers and expression of Foxp3. 
The mode of action of Tregs is not fully understood yet. It is accepted that 
suppression is mediated via a cell – cell contact dependent mechanism as was 
proved by transwell experiments [63]. The role of suppressive cytokines, which 
are the suppressive mediators of inducible regulatory T cells, is a controversial 
issue. In 2001 Nakamura et al. suggested that TGF-ß was the mediator of 
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suppression not in its soluble form but bound to the cell membrane of Tregs 
[64]. They and others showed that Tregs express TGF-ß on their cell surface, 
that antibodies directed against this cytokine abolished suppression of 
responder T cells and that membrane bound TGF-ß on Tregs can only exert 
suppression as long as it is biological active. Other in vitro studies do not 
suggest necessity for cytokines, because Tregs still suppress responder T cells 
when blocking antibodies against IL-10 and TGF-ß are added to the media [33, 
63, 65].  
It is also suggested that Tregs are capable to induce a suppressive phenotype 
in CD25- responder T cells – termed infectious tolerance [50] – which become 
inducible Tr1 or Th3 cells.  
There are several key molecules whose deficiency or functional alteration 
affects the generation or function of Tregs. Although it is known that there are 
essential molecules for Treg function, markers proposed for this cell type are 
also known to be expressed on activated T cells, like the IL-2Rα chain (CD25). 
Other surface markers are CD62L, CD58, GITR, CD122, CD45R0 and MHC II 
[65]. In vitro model systems have identified a long list of molecules and 
processes that contribute to Tregs suppressive activities, but it remains unclear 
whether any of the conclusions drawn from these studies shed light on how 
Tregs function in vivo [35]. 
 
Foxp3 – The master regulator of Tregs 
 
As mentioned it has been shown that naturally occurring Tregs highly express 
the transcription factor Foxp3. Although it seems in mice to be uniquely 
expressed in Tregs in humans Foxp3 expression is also observed in activated T 
cells [43].  
Foxp3 first gained attention for its importance in Tregs after identification of 
natural mutations in the gene encoding Foxp3. These cause a fatal autoimmune 
disorder known as immune dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) in humans [66] and the scurfy phenotype in Foxp3 knock out mice 
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[67]. Patients who suffer from this disease have massive lymphoproliferation, 
diabetes mellitus, thyroiditis, eczema, enteropathy and allergies already early in 
life. 
Foxp3 belongs to a family of transcription factors that is characterized by a 
winged helix-forkhead DNA-binding domain called forkhead box (Fox). High 
homology exists between human, mouse and rat. So far little is known about 
biochemical pathways by which Foxp3 might act although it is predicted to be a 
transcriptional repressor [68]. It was reported that transgenic expression of 
Foxp3 inhibits endogenous cytokine expression which is driven by NFAT and 
NFκB in conventional T cells [69]. Foxp3 itself is thought to be regulated by the 
oestrogen promoter on the transcriptional level. It has a direct binding site in the 
promoter region and furthermore there are reports that TGF-ß can induce 
Foxp3 expression through the activation of the SMAD signalling cascade [70]. 
There is a growing number of publications that show that decreased Foxp3 
expression correlates with decreased Treg function, especially in the murine 
system. To sum up; Foxp3 plays a central role in Treg development and 
function.  
 
Role of Foxp3 in human CD4+CD25+ Tregs 
 
It is now well established that human and mouse natural occurring Tregs 
express high levels of Foxp3 constitutively. However, in contrast to results 
described in murine cells, in humans it is still controversial whether Foxp3 
overexpression in naive CD4+ T cells is sufficient to confer a regulatory function 
[43]. Allan et al. show that retroviral mediated ectopic expression of Foxp3 in 
CD4+CD25- T cells does not result in a strong and stable suppressive capacity 
equivalent to that of natural CD4+CD25+ Tregs [71], whereas Sakaguchi and 
coworkers reported high suppressive activity after Foxp3 gene transfer [72].  
Foxp3 is a faithful marker for Tregs in the mouse, and both necessary and 
sufficient for their development and function. Initial work in human systems 
supported this conclusion, with Foxp3 being found only in CD4+CD25+ T cells 
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with in vitro suppressor activity [48]. However, Walker et al. showed that TCR 
stimulation of CD4+CD25–Foxp3– T cells led to the induction of Foxp3 
expression in those cells that also upregulated CD25 [73]. 
In human cells, Foxp3 is also expressed by activated non-suppressive 
CD4+CD25- effector T cells [71] suggesting that in addition to this transcription 
factor other components may be required for optimal suppressor activity [68]. 
Upon activation, human effector CD4+CD25– T cells and also Tr1 cells can 
express Foxp3, albeit transiently. The role of transient Foxp3 expression in Teff 
cells is poorly understood but it is becoming clear that it does not correlate with 
suppressor function (Figure 1) [43]. The initial studies indicating that Foxp3 was 
exclusively expressed in human naturally occurring Treg have been disputed. In 
human CD4+ Teff cells, induction of Foxp3 expression upon activation occurs in 
dividing cells and does not interfere with proliferation and cytokine production of 
these cells [74]. 
Human and mouse Tr1 cells generated in vitro do not constitutively express 
Foxp3, but upon activation can up-regulate this transcription factor to levels 
similar to those observed in activated Teff cells [75].  
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Figure 1. Human Teff cells and regulatory T cells; a complicated picture  
In the thymus, naturally occurring CD4+Foxp3+ Treg and conventional 
CD4+Foxp3– cells are generated. In the periphery, naturally occurring Tregs 
maintain high sÄtable expression of Foxp3. It is still a question whether 
naturally occurring Tregs can become IL-10-producing Tregs. Conventional 
CD4+ T cells, after TCR engagement, can either transiently up-regulate Foxp3 
and become effector T cells or stably express Foxp3 and become induced Treg. 
Moreover, conventional CD4+ T cells upon encounter with the antigen in the 
presence of IL-10 become adaptive Tr1 cells, which do not stably express 
Foxp3 [43]. 
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Dendritic cells 
 
A short history  
 
In 1868, dendritic cells (DCs) were discovered in human skin by Paul 
Langerhans [76]. These cells were named Langerhans cells (LCs) after their 
discoverer who, due to their dendrites, regarded them as neurons. Steinman 
and Cohn identified DCs in peripheral lymphoid organs of the mouse in 1973 
[77]. Also Katz et al. reported that skin epidermal LCs derive from cells that 
originate in the bone marrow [78]. These and many other studies inspired active 
research in the 1980s that defined many of the structures and fuctions of LCs 
and DCs. Their role as the key cell type in the regulation of an adaptive immune 
response was defined. 
 
Role of DCs 
 
Efficient host defense depends on a concerted action of antigen nonspecific 
innate and antigen specific adaptive immunity. The innate immune system 
rapidly recognizes antigens by shared patterns. Adaptive immunity is 
distinguished by the capability to rearrange immunoglobulin genes and to 
establish immunological memory. DCs link these two parts by capturing and 
presenting antigens resulting in the initiation of adaptive immunity. DCs are the 
“sentinels” of the immune system are distributed in most tissues, where they 
reside as immature cells with high phagocytotic capacity [79].  
Following antigen uptake DCs can mature and migrate to lymphoid organs. 
Maturation can be induced by several danger signals for example bacterial LPS, 
CpG and viral double stranded (ds) RNA. In the secondary lymphoid organs, 
mainly the draining lymph node, DCs interact with antigen-specific T cells 
initializing an immune response. DCs are the only APC able to stimulate naive T 
cells and to induce primary immune responses and are therefore also called 
professional APCs [80, 81].  
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DCs are less defined by phenotypic markers than by their morphology and their 
function. The term “dendritic cell” refers to their extraordinary shape, which is 
marked by large cell membrane processes or veils [77]. Immature DCs are well 
equipped to capture antigen. They apply several mechanisms like 
macropinocytosis, receptor-mediated endocytosis via C-type lectin receptors 
(mannose receptor, DEC 205), or Fc-gamma receptor types I (CD64), or II 
(CD32) or phagocytosis of particles like apoptotic or necrotic cell fragments, 
viruses or bacteria [81].  
Several factors including pathogen-derived signals like LPS, CpG and dsRNA, 
cytokines and T cell derived signals can induce DC maturation [79]. During 
infections, DCs are activated by stimulatory signals from invading pathogens, 
called pathogen-associated molecular patterns (PAMPs), which are recognized 
by pattern recognition receptors (PRRs) [82]. Classical PAMPs are for example 
LPS, an integral part of the cell wall of Gram-negative bacteria, which is 
recognized by Toll-like receptor (TLR)-4, and lipopeptides from bacterial cell 
walls and dsRNA, signaling through TLR-2 and TLR-3, respectively [83, 84].  
Maturation of DCs goes along with far-reaching changes converting them from 
cells specialized on antigen uptake to cells specialized on antigen presentation. 
Costimulatory and adhesion molecules like CD40, CD54, CD58, CD80 and 
CD86 are upregulated and MHC II, which is already synthesized, is 
redistributed from intracellular compartments to the plasma membrane. The 
capability to endocytose declines and cytoskeleton reorganization permits a 
higher motility [80, 81]. Chemokines guide the mature DCs via the afferent 
lymph to the T cell area of the draining lymph nodes where additional 
maturation signals like CD40L and RANKL are provided by T cells.  
 
Antigen presentation 
 
DCs encounter naive T cells in the T cell areas of secondary lymphoid organs 
where they stimulate their proliferation, their differentiation or their deletion [85]. 
In the area of contact between T cells and DCs adhesion molecules, like 
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integrins ß1and ß2, CD2 and ICAM-3 on the T cell and ICAM-1, ICAM-2, LFA-3 
and DC-SIGN on the APC, are arranged around the center of the synapse: This 
center is made up of the TCR and costimulatory molecules [30]. Adhesion 
molecules like the ICAM-3-binding lectin DC-SIGN, which is specifically 
expressed on monocyte-derived DCs, are responsible for the initial contact and 
for the maintenance of interaction [86]. It is supposed that the duration of TCR 
stimulation together with polarizing cytokines determines the direction of the 
response. T cells, which receive a short TCR stimulation in the absence of IL-12 
proliferate, but do not differentiate into effector cells. A secondary antigenic 
stimulation triggers their differentiation [87]. Once a naive T cell is activated it 
can stimulate DCs via CD40L to increase the expression of the costimulatory 
molecules CD80 and CD86 and to release cytokines. 
By sampling different self-antigens and presenting those to T cells, DCs are 
suggested to play also a critical role in the induction of peripheral tolerance. 
Thereby DCs are proposed to be involved in the prevention of autoimmune 
diseases. The state of DC maturation seems to be an important aspect: 
Immature, resting DCs are relatively poor stimulators of T cell proliferation and 
can induce in context of auto-antigens regulatory T cells. Naive CD4+ T cells 
when repetitively stimulated with allogeneic iDCs were shown to differentiate 
into non-expanding regulatory T cells in vitro [53]. 
 
Dendritic cells and pathogens 
 
The major entry sites for pathogens are the epithelial surfaces of the mucosa 
and the skin. Following antigen deposition DCs are rapidly recruited (within 1 
hour) to mucosal surfaces [88]. In the epithelium DCs can get into contact with 
pathogens or their components by different antigen-uptake mechanisms, or they 
get infected themselves. The recognition of microorganisms occurs by means of 
receptors for pathogen-invariable structures like TLRs. Beside the regular MHC 
class I and II presentation pathways, cross-presentation plays an essential role 
in immune responses to pathogens. Cross-presentation enables the induction of 
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CTL responses to pathogens that do not infect DCs and it allows CTL 
responses even to pathogens that trigger apoptotic death of DCs, inhibit 
maturation or otherwise impair DC function [89].  
DC migration from the periphery to lymph nodes serves to activate T cells, but it 
can also be exploited by pathogens. For example HIV-1 binds to the DC-
specific lectin DC-SIGN (CD209). The infectious particle is transported on the 
DC surface to the lymph nodes, where it infects CD4+ T cells in trans [90]. 
There are many mechanisms for pathogens to evade host immune responses. 
Microorganisms impair the recognition of infected cells, the acquisition and 
processing of antigens or the maturation of DCs. Poxviruses and Herpesviruses 
impair the recruitment of DCs by secreting chemokine-receptor homologs that 
bind locally produced chemokines. Some viruses try to circumvent antigen-
presentation by destruction of DCs: Canarypox and vaccinia virus infect DCs 
and induce apoptosis. Herpesvirus and Vacciniavirus can inhibit DC maturation. 
Herpesvirus also impairs DC migration to lymph nodes by inhibition of CCR-7 
upregulation [89]. Likewise, pathogens are able to alter the interaction between 
DCs and T cells. For instance, following measles virus infection DCs mature, 
but are not able to stimulate T cells. The measles virus partly impairs CD40L-
dependent activation of DCs and downregulates the production of IL-12, 
responsible for the differentiation of CD4+ T cells into Th1 cells [91]. Also 
Human rhinovirus induces the downregulation of IL12 production by monocytes, 
but also leads to the release of the immunosuppressive cytokine IL-10 that may 
contribute to the disturbed cellular immune response during HRV infections [92]. 
But more about HRV in the next chapter.  
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Human Rhinovirus (HRV)  
 
HRV overview 
 
Rhinovirus is a genus of positive, single-stranded RNA viruses belonging to the 
family of Picornaviridae. The HRV genome consists of one plus strand RNA 
molecule of about 7200 bases. The Picornaviridae include small (greek: pico) 
RNA-containing viruses without envelope. Other members of the Picornaviridae 
family are for example the enteroviruses, such as poliovirus and Coxsackie 
viruses. The whole Picornaviridae family consists of 5 genera: hepato-, entero-, 
cardio-, aptho- and rhinoviruses [93].  
Thus far, there are >130 rhinovirus serotypes identified [94]. HRV serotypes are 
phylogenetically subdivided into three groups; HRVA, HRVB and HRVC, based 
on sequence comparison [93, 95]. Rhinoviruses can also be further divided, 
depending on receptor utilization, into major group Rhinoviruses, which bind to 
ICAM-1 (Intercellular adhesion molecule 1) and minor group Rhinoviruses 
binding LDL-R (Low Density Lipoprotein Receptor) and related receptors [96, 
97]. More than 90% of Rhinoviruses belong to the major group [98].  
 
HRV structure 
 
HRV are non-enveloped viruses with an icosahedral capsid enclosing a single-
stranded, positive-sense RNA genome that is translated after cell entry [98]. 
The three-dimensional structure of rhinoviruses was examined via X-ray 
cristallography [99]. The naked icosahedral capsids measure approximately 20-
30 nm. The rhinovirus capsid, which protects the central RNA core, is 
composed of 60 copies (protomers) of each of 4 structural proteins. Virus 
protein 1 (VP1), VP2, and VP3 are located on the capsid surface and are 
responsible for its antigenic diversity. The fourth protein, VP4, is located inside 
the virus and anchors the RNA core to the viral capsid [96]. The VP1 protein is 
the most surface-exposed one of the rhinovirus capsid proteins, and it contains 
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a number of major epitopes recognized by neutralizing antibodies [100].  
Each of the twelve 5-fold axis of HRV is encircled by a 20 Å deep and narrow 
canyon. This depression is the receptor binding site. HRV receptors were 
predicted as small molecules fitting into the depression and binding to 
conserved residues, while antibodies were suggested to be hindered to enter 
the canyon and permitted HRV to escape host T cell immune response. This 
suggestion was called the canyon hypothesis [101]. But later X-ray structures 
proved that antibodies exist, binding to conserved residues within the canyon 
[102].  
 
HRV - The major cause of common cold in humans 
 
The common cold with its characteristic symptoms is one of the most frequent 
and familiar illnesses in humans. The majority of colds is caused by HRV, by 
one of over 100 serotypes. In normal individuals HRV causes only mild 
symptoms like sneezing, nasal congestion, cough, nasal obstruction, sore 
throat, rhinorrhea and headache. Colds partly result in sinus infections and otitis 
media. In patients with asthma or cystic fibrose a HRV infection can be harmful 
by worsening symptoms [103]. An HRV infection normally starts by self-
inoculation with the virus by hand into the nose or into the eyes, from where the 
virus comes via the lacrimal duct into the nose [104]. 
The optimal replication temperature of HRV is at 33°C. Due to this, HRV was 
supposed to infect only the upper respiratory tract. But it was shown that HRV is 
also capable to infect the lower airways, maybe contributing to exacerbations of 
asthma, pneumonia, bronchitis and cystic fibrose [105].  
 
ICAM-1 (CD54)  
 
The intercellular adhesion molecule 1 (ICAM-1) is a single-span, membrane- 
anchored glycoprotein, a member of the immunoglobulin superfamily and 
composed of five immunglobulin domains. ICAM-1 has important functions in 
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cell-cell adhesion, in inflammation and immune responses. It is expressed on 
endothelium and functions in leukocyte binding to the blood vessel wall and in 
transendothelial emigration at inflammatory sites. ICAM-1 can be induced on 
many cell types like connective tissue cells, monocytes and antigen-presenting 
DCs, or up-regulated, like on B cells in germinal centers or epithelial cells. 
Among the cells, which constitutively express ICAM-1 are epithelial cells of the 
nasal mucosa. ICAM-1 is important in adhesion of leukocytes and endothelial 
leukocyte migration and accumulation through binding to its cellular ligands 
LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) [106]. It is also an essential 
co-stimulatory receptor on APCs. Mice deficient in ICAM-1 fail to recruit 
leukocytes to inflamed tissues [107].  
ICAM-1 is the major group rhinovirus receptor, it serves >90% of rhinovirus 
serotypes, whereas some of the remaining minor group rhinoviruses bind 
members of the low-density lipoprotein receptor family [108]. Rhinovirus 
attachment to ICAM-1 initiates entry into the host cell with insertion of the virus 
genome and thus infects the cell [109]. 
Additionally ICAM-1 is exploited from several other pathogens. A-type 
coxsackieviruses like HRV, use the binding to ICAM-1 for triggering RNA 
release into the host cell. Plasmodium falciparum binds endothelial cells via 
ICAM-1 and invades; HIV-1 uses ICAM-1 as a coreceptor [110, 111].  
 
Infection cycle 
 
Following attachment to ICAM-1 the virus releases its RNA and bound VP4 into 
the cytosol of the host cell. Receptor binding of major group viruses leads to 
conformational changes of the capsid, which facilitate together with a low pH 
uncoating within endosomes and release of viral RNA [112]. These changes 
would result in a higher affinity binding between ICAM-1 and HRV through a 
temperature-sensitive distortion of VP1. This movement occurs only at 
temperatures > 30°, correlating with body temperature. VP1 would act as a 
hinge inducing a destabilisation of the capsid and opening a channel at the 5 
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fold axis for release of RNA [111, 113]. 
The plus strand RNA is released into the host cytosol, where it directly acts as 
mRNA. Translation is initiated by binding of ribosomes to the IRES (internal 
ribosomal entry site). The RNA is translated by polysomes, carrying up to 40 
ribosomes. The produced polyprotein has to be processed to obtain the mature 
proteins. The first cleavage is done by the protease 2A and leads to the 
liberation of the capsid protein precursor P1 from the rest of the molecule. 
Protease 3C performs the following cleavage steps [98]. Replication of new viral 
RNA starts with the production of complementary minus strand RNA to 
incoming plus strand RNA by a RNA-dependent RNA polymerase. The minus 
strands serve as templates for the synthesis of new plus strands.  
The crucial step for the start of virion assembly is the cleavage of the precursor 
protein P1, which forms immature protomers consisting of the tightly assembled 
proteins VP0, 3, 1. Increasing concentrations of immature (5S) protomers 
trigger the further association of pentamers and the packaging of plus-strand 
VPg RNA into the developing particles. The resulting 150S provirions are not 
yet infectious. A final maturation step by auto-catalytically cleavage of VP0 in 
the mature protomer proteins VP2 and 4 leads to infectious virions. The mature 
virions are released by cell lysis [98]. Assembled mature virions are released 
from the cell after 8–10 h by cell lysis of epithelial cells. 
 
Immune response to HRV 
 
The typical common cold symptoms were originally considered to be produced 
by HRV induced destruction of the nasal mucosa. This assumption was 
disproved by examination of nasal epithelium in biopsy specimen from people 
with natural cold. Surprisingly the nasal epithelium was shown to be intact. The 
only distinguishing feature during common cold was the increased number of 
polymorphonuclear neutrophils invading into the submucosa and epithelium 
[114]. HRV replicates only in a small number of mucosal cells and is only 
slightly inducing cytopathic effects [115]. The conclusion was that the cold 
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symptoms were induced by the host response itself. The viral infection seems to 
trigger an inflammatory cascade [116].  
HRV infection of primary epithelial cells and epithelial cell lines is accompanied 
by a release of inflammatory mediators in vivo and in vitro. In particular pro-
inflammatory cytokines including IL-1ß, TNF-α, IL-8, IL-6 and IL-11 and the 
vasoactive peptides bradykinin and lysyl bradykinin [117]. In addition, 
chemokines such as Rantes, MCP-1 and IP-10 as well as the angiogenic factor 
VEGF have been found in nasal secretions of patients with colds [117]. As a 
result, it is now considered that common cold symptoms result from an 
inflammatory ‘cytokine disease’ of the host in response to the virus and not from 
the virus itself. Attracted by these mediators, inflammatory leukocytes, 
granulocytes, DCs and monocytes are found to migrate to the site of HRV 
infection [118]. Especially neutrophil infiltration into the submucosa and 
epithelium was observed during the common cold and may be caused by IL-8, 
which is a potent chemoattractant and mediator for the invasion of neutrophils 
[119]. 
Antibodies against HRV are detectable in the serum 5-7 days after onset of 
illness. The rise in serum antibodies, mostly IgG, goes along with the rise of 
antibodies in secretions, mostly IgA. The antibody response has no role in 
recovery from infection, because it starts when the symptoms already cease 
[120]. 
HRV also stimulates nonspecific activation of lymphocytes through a monocyte-
dependent mechanism, supposed to enhance airway inflammations involved in 
the exacerbations of asthma [121]. In certain in vitro experiments 
immunosuppressive effects of HRV are seen. These would correlate with the 
fact that HRV infections often promote secondary bacterial infections due to a 
hindered immune response. High concentrations of HRV were shown to inhibit 
the T cell responses to memory-antigens and also the responses of cytotoxic T 
cells to alloantigens, but not responses to mitogens, IL-2 or natural killer cell 
function [122]. HRV binding to monocytes was shown to induce the 
immunosuppressive cytokine IL-10 and to inhibit the activating cytokine IL-12 
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and results in inhibition of antigen-specific T cell responses [92]. 
 
HRV immune evasion 
 
A virus’s success is directly dependent on its ability to mount an effective anti 
immune response within the host. As a consequence of this, successful viruses 
have developed a broad range of mechanisms to manipulate, modulate or shut 
off key functions of the host immune system [123, 124]. 
Rapid replication and antigenic variation are critical immune evasion 
mechanisms of small RNA viruses [124]. Therefore the large number of 
serotypes combined with a high mutation-rate might be part of the success of 
HRV infections. However, the intrinsic antigen-variations of HRV do not explain 
why, despite recruitment of leukocytes, appropriate immune responses appear 
to be dysregulated or hindered in the respiratory tract upon HRV infection. Also 
HRV bind to but do not infect or damage leukocytes [92,121].  
 
Modulation of leukocyte interactions 
An efficient anti-immune response strategy of certain viruses is the selection of 
an immunologically relevant cellular receptor. As mentioned, the vast majority of 
HRV uses the cell surface receptor ICAM-1 to bind to and infect epithelial cells. 
ICAM-1 is an essential co-stimulatory receptor on APCs and ICAM-1-deficient 
APCs have a strongly impaired capacity to induce T cell responses [125]. Thus, 
HRV can directly interact with leukocytes and since the binding site of HRV on 
ICAM-1 overlaps with the binding site of LFA-1, it is intriguing that binding of 
HRV to leukocytes might have profound functional consequences. This was 
demonstrated; ICAM-1 expressed on the surface of human fibroblasts functions 
as a receptor for HRV as well as a receptor for LFA-1 bearing human T cells, 
which could be inhibited by an antibody to ICAM-1 [126]. Interestingly, binding 
of HRV to fibroblasts inhibited the subsequent adhesion of T cells. HRV16, a 
major group HRV, significantly inhibited T cell proliferation induced by antigen 
but not proliferation secondary to mitogens, IL-2, or an irradiated allogeneic T 
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cell line. Noninfectious (UV-irradiated) HRV had similar effects. Inhibition of T 
cell proliferation was dependent on HRV binding to ICAM-1 on monocytes, 
indicating that the virus interferes with lymphocyte activation indirectly through 
effects on antigen-presenting cells [122].  
HRV is a natural ligand for ICAM-1 with special binding and consequently 
signaling features. One HRV capsid has 60 potential binding sites located in 
depressions of the viral protein coat, the so called canyons [113]. Due to the 
multivalency of binding sites on HRV particles, this allows high avidity 
interactions with their receptors. Therefore, HRV can be considered to resemble 
a perfect cross link. It was investigated by our lab, whether HRV binding to 
ICAM-1 might influence the adhesiveness of leukocytes [127]. Engagement of 
ICAM-1 with HRV14 on human mononuclear phagocytes induces homotypic 
clustering of monocytes and monocyte-derived DC (but not in lymphocytes) 
which was found to critically involve homophilic PECAM-1 interactions and is 
mediated via LFA-1/ICAM-3. 
Data from another study from our lab suggest that HRV may polarize monocyte 
differentiation towards a ‘Th-3 phenotype’. HRV14 efficiently inhibit antigen-
specific T cell responses. These inhibitory effects were found to result from a 
particular spectrum of cytokines released by mononuclear phagocytes upon 
HRV14 interaction. Most prominent among them is IL-10, which is a well-
established immunosuppressive cytokine, which is strongly induced by HRV14 
[92]. 
 
Immune Evasion by Targeting DC 
DCs are the most potent APCs and play a central role in the generation of 
primary T cell responses and the maintenance of immunity. Because of their 
importance in initiating antiviral immune responses, DCs are ideal targets for 
viral immune evasion strategies. Several viruses are known to modulate DC 
function and thus impair antiviral T cell responses. The result can be a transient 
or prolonged suppression of the immune response, often associated with 
secondary microbial infections or the initiation of a persistent infection. A 
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particularly efficient trick of viruses, e.g. measles, vaccinia virus, CMV or HIV, is 
the targeting of the co-stimulatory function of DC. Thereby the virus is able to 
prevent pathogen specific immunity (i.e. ignorance) and, even more effective, is 
able to induce pathogen-specific tolerance, when DC present antigens in the 
absence of costimulatory signals [124, 128].  
 
HRV14 has an immune modulatory effect on monocyte-derived DC 
We have recently demonstrated that upregulation of inhibitory accessory 
molecules on DC represents another efficient viral strategy to turn off antigen-
specific immune responses. HRV can blunt adaptive immune responses 
through the induction of a novel DC activation program. Cocultivation of DCs 
with HRV-14 (R-DCs) induces the expression of inhibitory receptors B7-H1 (PD-
1L, CD274) and sialoadhesin (Sn, Siglec-1, CD169), a sialic acid binding lectin, 
on the R-DCs surface, without affecting the expression of stimulatory receptors 
such as CD80 or CD86. HRV14 fails to mature DC, also R-DCs have a 
diminished T cell stimulatory capacity. The consequence of this altered 
accessory repertoire on R-DCs is that cocultured T cells acquire a deep anergic 
state [123, 129]. 
Since monocytes are the precursor cells of our DCs, we expected that IL-10 
production induced upon co-culture of DC with HRV14 was involved in this 
process. Although small amounts of IL-10 are produced by R-DC, neutralizing 
antibodies against IL-10 failed to reverse the inhibitory effect of HRV14. Thus, 
HRV seemingly modulates the accessory function of mononuclear phagocytes 
and DC through different mechanisms. Importantly, HRV14 effects were not 
detectable upon addition of the virus to the MLR cultures or due to a brief 
pretreatment of DC with HRV14 but required a co-culture of at least 24 h. 
During this time, HRV14 obviously modulates the co-stimulatory repertoire of 
DC in a special way. We could indeed identify two of such receptors on R-DC, 
which seem to deliver inhibitory signals to T cells: B7-H1 and sialoadhesin 
[129].  
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Figure 2. The B7 family 
 
 
B7-H1, a member of the B7 molecule family, is a well-defined accessory 
molecule with inhibitory effects through its receptor PD-1 on the T cell side 
(Figure 2) [130]. B7-H1 is critically involved in the induction and maintenance of 
T cell anergy induced by IL-10- treated DC [131]. Yet, blocking of B7-H1 was 
not sufficient to revert the deep anergic state in T cells triggered by R-DC. Since 
other inhibitory accessory molecules on DC are not characterized so far, it was 
necessary to search for such candidate structures on R-DC. S.Kirchberger 
could identify sialoadhesin as that inhibitory accessory molecule on R-DC 
(Figure 3) [129].  
Sialoadhesin is a member of sialic acid binding lectin family of I-type lectins 
which preferentially binds to sialylated carbohydrate structures (e.g. NeuAca2,3-
Gal) [132]. Sialoadhesin is a frequently used marker for macrophages because 
it is not expressed on monocytes, lymphocytes and DC. Our finding that 
sialoadhesin is strongly induced on DCs upon HRV14 treatment after 1–2 days 
correlates with the appearance of the inhibitory phenotype of R-DC. CD43 has 
been recently described as ligand for Sn on T cells [133]. 
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 Figure 3. HRV14 inhibits the accessory function of DCs 
In a previous study of our lab it was found by using an antibody-based screen, 
that B7-H1, a recently described inhibitory member of the B7 family and 
Sialoadhesin, a lectin which belongs to the Siglec family, are strongly 
upregulated on R-DC. These molecules are also involved in the weak T 
stimulatory function of R-DC, as blocking of these molecules by antibodies 
restored T cell proliferation. Adapted from Kirchberger et al [129]. 
 
 
Now, we decided to further examine the function of these R-DC treated T cells. 
What we already knew was that the consequence of this altered accessory 
repertoire on R-DC is that co-cultured T cells acquire a deep anergic state. 
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The IL-12 cytokine family 
 
Cytokines are the major mediators of host defense, they regulate 
communication between APC, lymphocytes and other host cells in the course of 
inflammation, infection and antigen specific immune responses. Cytokines are 
autocrine and paracrine signalling peptides which essentially act between 
immune cells temporally and spatially [134]. Most of them are immediately 
released into the surrounding interstitial fluid upon biosynthesis [135], modulate 
the functional activities of individual cells and tissues, thereby mediate 
interactions between cells directly and regulate processes taking place in the 
extracellular environment. Cytokine expression is normally transient and can be 
regulated at all levels of gene expression [136]. Multiple cytokines often have 
overlapping ubiquitous biological activities so that their physiologic significance 
as normal regulators is often difficult to assess [137]. This is explained in part by 
the sharing of common receptor subunits among members of the cytokine 
family. A single cytokine may elicit reactions under certain circumstances, which 
are the reverse of those seen under other circumstances. Various factors can 
influence the effects of a certain cytokine like: the type, the duration, the growth 
state of the responder cell, the type of neighbouring cells or the combination of 
other cytokines present at the same time together with the temporal sequence 
of several cytokines acting on the same target cell [134]. Regulation of this 
system is of great importance and for example several cytokines are inhibited 
by other cytokines or soluble factors [138]. A number of viruses exploit these 
facts to evade immune responses of the host.  
The interleukin- 12 (IL-12) cytokine family remains one of the most important 
ones and includes IL-12, IL-23, IL-27, and the recently identified IL-35. IL-12 
cytokine family members differ from other type I cytokine superfamily members, 
because they are heterodimeric complexes.  
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IL-12 
 
Interleukin-12 is a 70 kD heterodimer consisting of two subunits, designate p40 
and p35 and signals through a heterodimeric receptor. The p40 subunit shows 
similarities to cytokine receptors and the p35 subunit is related to Granulocyte-
Colony Stimulating Factor and IL-6. For IL-12 signaling, the IL-12p40 subunit 
interacts primarily with IL-12Rb1, while p35 binds to IL-12Rb2 [139]. IL-12 is 
mainly produced by activated APCs (monocytes, macrophages,DCs, 
neutrophils and B cells) and has been shown to play a role in differentiation and 
expansion of Th1 responses [140]. Beside its effects on Th1 responses it was 
shown that IL-12 is required for the generation of CTLs [141, 142]. Inhibition of 
IL-12 production occurs via the release of IL-10, IL-11, IL-13 and type 1 
interferons (IFNs) [143]. 
 
IL-23 
 
In 2000, p19, was identified on the basis of its homology with IL-6 and the p35 
chain [144]. This protein was shown to associate with the p40 chain to form 
another heterodimeric cytokine known as IL-23. IL-23, like IL-12, is a pro-
inflammatory cytokine that induces IFN-gamma production and promotes the 
Th1 response. IL-23 participates in a positive feedback loop promoting IL-12 
production by DCs to enhance p19 transcription and further IL-23 production. 
However, in the absence of IL-23, IFN-gamma production and Th1 
differentiation are normal [145], indicating that while IL-12 and IL-23 can 
synergize for maximal Th1 induction, IL-23 is not absolutely required for Th1 
differentiation. IL-23 also has a role in promoting natral killer (NK) cell activity, in 
that IL-23 synergizes with IL-12, IL-18, and IL-2 to promote IFN-gamma 
production by NK cells [146]. A Th1 independent function of IL-23 has also been 
elucidated. Unlike the other IL-12 family cytokines, IL-23 promotes the survival 
of Th17 cells induced by IL-6 and transforming growth factor ß (TGF-ß) [147]. In 
fact, exposure to IL-23 and IL-1 is necessary for full effector differentiation and 
function of Th17 cells [148]. The IL-23 receptor is composed of IL-12Rb1 and 
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the novel receptor chain IL-23R [146]. 
 
IL-27 
 
IL-27 comprises the p28 and EBI3 (Epstein–Barr virus-induced gene 3) chains 
and displays homology with the p35 and p40 chains, respectively [149]. 
Following the discovery of IL-27, initial reports indicated that IL-27, in 
combination with IL-12, enhanced the production of IFN-gamma by naive T cells 
and NK cells by promoting expression of T-bet and IL-12Rb2 [150]. This 
observation suggests that IL-27 sensitizes T cells to the effects of IL-12 and is 
critical for the early events leading to Th1 cell polarization. However, more 
recently, of immunomodulatory functions have been ascribed to IL-27 as 
reviewed by Stumhofer and Hunter [151]. It is indicated that IL-27 can inhibit 
Th1- driven infections, limit Th2 activity toward Leishmania major and block the 
development of Th17 and TGF-ß driven induced Treg formation [152]. Like IL-
12, IL-27 can directly inhibit secretion of IL-4 and antagonize IL-2 production, 
hence limiting Th2 cell differentiation and effector cell function [153]. IL-27 
signals through a heterodimeric pairing of gp130 and the previously orphaned 
receptor chain WSX-1 [147, 154]. 
 
IL-35 
 
Quite recently a new member of the IL-12 family, called IL-35, was described. 
IL-35 is a heterodimeric cytokine consisting of EBV-induced gene 3 (EBI3) and 
the p35 subunit of IL-12 and has a size of 78 kDa [155]. The discovery of this 
cytokine further confirms that many pairings of IL-12 family proteins are 
possible, as EBI3 binds to p35.  
EBI3 is a homologue to IL-12p40, and was discovered in EBV (Epstein Barr 
virus) infected B lymphocytes [156]. EBI3 is also a part of IL-27. The EBI3 
protein has a size of 34 kDa. While p35 is constitutively expressed in most 
tissues, EBI3 is mainly expressed in hematopoetic cells. Its expression was 
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discovered in lymphoid blasts of reactive lymphoid organs, in the light zone of 
germinal centers, where B lymphocytes are associated to T cells. A splice 
variant of EBI3 was described to be located in the spleen, liver and kidney 
[157]. It was also demonstrated that EBI3 is expressed throughout pregnancy 
by syncytiotrophoblasts and extravillous trophoblasts and the levels of EBI3 are 
strongly up-regulated in sera from pregnant women [158]. Intestinal epithelial 
cells (as initial APCs) constitutively express EBI3 (comparable to p35) and the 
expression level is up-regulated through IL-1α or TNF-α addition. In contrast, 
the p35 level is also increased in the presence of IFN-gamma [159]. It is 
proposed that free, latent EBI3 homodimer produced by APCs acts as an 
antagonist of IL-27 and therefore prevents any further IL-27 stimulation of naive 
T cells [149]. 
Collison et al. demonstrated that the EBI3–p35 heterodimeric complex is 
constitutively produced by mouse regulatory T cells and not effector T cells. In 
particular EBI3 is strongly overexpressed in Tregs. In this study, EBI3–/– and 
p35–/– regulatory T cells had reduced regulatory activity both in vitro and in 
vivo, which indicated that IL-35 is required for the suppressive activity of 
regulatory T cells, at least in mice [160]. IL-35 has been shown to expand 
murine CD4+CD25+Foxp3+ regulatory T cells, if T cells are cultivated under 
strong inductive conditions with polyclonal T cell receptor activation and the 
presence of costimulatory signals [155]. IL-35 is required for the suppressive 
activity of regulatory T cells, and EBI3 is a downstream target of Foxp3, a 
transcription factor that is required for Treg development and function [160-162].  
IL-35 also downregulates the production of IL-17 under Th17-inducing 
conditions and was shown to attenuate collagen-induced arthritis [155]. In the 
same paper IL-35 was also shown to suppress the proliferation of CD4+CD25- 
murine effector T cells, but expand the proliferation of CD4+CD25+ Tregs. 
IL-35 inhibited clinical manifestation of collagen-induced arthritis or could cease 
further disease exacerbation upon initiation of IL-35 treatment [155]. Exogenous 
IL-35 treatments suppressed Th1 and Th17 cells and promoted CD39 
expression by CD4+ T cells. Sorted CD25-CD39+CD4+ T cells from IL-35-treated 
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mice produced IL-10 and, upon adoptive transfer, were sufficiently potent to 
inhibit subsequent development of inflammation in mice with collagen-induced 
arthritis. IL-35 stimulation of CD39+ regulatory T cells confers protection against 
collagen II-induced arthritis via the production of IL-10 [163]. 
In contrast to all the murine data, human CD4+CD25+Foxp3+ regulatory T cells 
do not constitutively express IL-35 and induction of Foxp3 does neither 
upregulate EBI3 nor p35 mRNA. IL-35 does not contribute to the suppressive 
function of Foxp3 induced human Tregs [164, 165]. Nevertheless EBI3 
transcripts are found in activated effector CD3 positive T cells and p35 is 
described to be constitutively expressed in various T cell subsets. [164, 165]. 
In addition, previous work from 1997 indicated that EBI3 and p35 are highly 
expressed in human placental trophoblasts, as shown by co-precipitation 
experiments. These findings suggest that, IL-35 may be an immunomodulator at 
the feto-maternal border [166]. Whether this effect is due to Treg mediated 
suppression of maternal responses to the fetus or due to the suppressive 
capacity of other cell types that might secrete IL-35 remains to be determined.  
Although many of the biological effects of IL- 35 are still being elucidated, it is 
clear that IL-35 directly suppresses Teff cell proliferation in vitro, in an APC free 
culture. Moreover, loss of IL-35 expression results in reduced in vivo 
suppressive capacity of Tregs [160]. How IL-35 can suppress in vivo Th17 
development and ameliorate collagen-induced arthritis [155] also requires 
further study. Also the receptor of IL-35 and the following signalling cascade 
remain to be explored.  
In summary, IL-35 is a novel inhibitory cytokine that is produced by Tregs and 
contributes to their suppressive activity. In contrast to all other known IL-12 
family members, which are not expressed by T cells, IL-35 is secreted by Treg 
cells. It functions in an inhibitory, rather than an immunostimulatory or 
proinflammatory, manner. Synonymous with differential expression, the IL-12 
cytokine family also exhibits distinct functional differences. While IL-12, IL-23 
and IL-27 share the common feature of inducing IFN-gamma production and 
promoting Th1 cell differentiation and proliferation, they act differentially on 
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subsets of T cells and with different kinetics. In contrast, IL-35 appears to 
function solely in an anti-inflammatory fashion by inhibiting T cell proliferation 
and perhaps other parameters [160]. 
The biological effects of IL-12, IL-23, IL-27 and may be also IL-35 are mediated 
through their interaction with their receptor chains that bind to and induce 
phosphorylation of the Janus kinase (Jak) family proteins [146]. Jak proteins 
then phosphorylate tyrosine residues on the intracellular domains of the 
receptor chains, which act as docking sites for various members of the signal 
transducer and activator of transcription (STAT) family. Phosphorylated STAT 
proteins form intramolecular complexes that translocate into the nucleus and 
bind DNA to initiate the gene expression [2]. 
All four members of the family are heterodimeric cytokines, composed of an 
alpha chain (p19, p28, or p35) and a beta chain (p40 or EBI3), and (may) signal 
through unique pairings of five receptor chains (IL-12Rb1, IL-12Rb2, IL-23R, 
gp130, and WSX-1) as also shown on Figure 4.  
Macrophages, DCs and monocytes can produce IL-12, IL-23 and IL-27 
following exposure to PAMPs that act through TLRs [167], this is not the case 
for IL-35, because it is described to be released by T cells (at least in mice). 
Due to the fact that APCs produce both IL-12 and IL-27, it is possible that IL-35 
is can also be produced by a subset of APCs, because APCs are equiped to 
produce both subunits of IL-35 (Figure 4).  
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Figure 4. The IL-12 cytokine family  
The interleukin- 12 (IL-12) cytokine family is of great importance and includes 
IL-12, IL-23, IL-27 and the recently identified IL-35. All four are heterodimeric 
cytokines, composed of an α chain (p19, p28, or p35) and a ß chain (p40 or 
Ebi3), and signal through unique pairings of five receptor chains (IL-12Rb1, IL-
12Rb2, IL-23R, gp130 and WSX-1); adapted from [161]. 
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Aim 
Human rhinoviruses (HRV) are the major cause of common cold in humans and 
are known to circumvent adaptive immune responses. Rhinovirus treated 
dendritic cells (R-DCs) have a strongly diminished T cell stimulatory capacity. T 
cells cocultured with R-DCs acquire a deep anergic state. Anergy is a hallmark 
of regulatory T cells that is why, in this study, we intended to explore if T cells 
co-cultured with R-DCs, also gain regulatory function.  
And if so, to identify the factor(s) responsible for the inhibitory nature of R-DC 
treated human T cells. 
 
 
Figure 5. Aim of study 
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Results 
 
Dendritic cells treated with human rhinovirus induce regulatory T cells 
 
Our laboratory has a longstanding interest in human rhinoviruses (HRV) and 
their interaction with immune cells. Kirchberger et al. recently found out that 
HRV is able to subvert the T cell stimulatory function of human dendritic cells 
(DCs). Cocultured T cells acquire a deep anergic state [129]. The first aim of 
this study was to investigate if T cells stimulated with HRV treated DCs (R-DCs) 
in addition to the already described anergy, also gain regulatory function. For 
that matter T cells were co-cultured with R-DCs and these T cells, after 
irradiation, added to an MLR. 
The results presented in Figure 6A demonstrate that addition of T cells, which 
were prestimulated with R-DCs, strongly inhibited T cell proliferation induced by 
untreated DCs in an MLR. Such an effect was not seen when T cells primed 
with untreated DCs were used.  
Prior fixation of R-DCs-induced Treg-cells with formaldehyde, reverted the 
inhibitory function as depicted in Figure 6B. Addition of the inhibitor WIN 52035-
2 at the time of transfer, which specifically blocks HRV binding to its cellular 
receptor ICAM-1 [168], did not remove the suppressive effect. This indicates 
that viral transfer is not involved in the inhibitory response (Figure 6C). 
Depletion of R-DCs from the coculture with T cells did not alter the results, the 
purified prestimulated T cells showed eminent inhibitory effects when added to 
an MLR. We conclude that T cells prestimulated with R-DCs are responsible for 
the inhibitory effect observed. 
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Figure 6. R-DCs induce Treg-cells  
(A) Human purified T cells (1x105) were stimulated with allogeneic DCs (1x104) 
alone (○) or in the presence of graded numbers of irradiated T cells, which had 
been preactivated with HRV-14 treated DCs (R-DCs, ▲) or mock treated DCs 
(∆). The Figure shows the result of one representative out of four independent 
experiments expressed as MV ± SD of triplicate determinations.  
(B) As in A, but the preactivated T cells (▲ and ∆) were fixed with formaldehyde 
(1%) before addition to the T cell proliferation assay. The Figure shows the 
result of one representative out of four independent experiments expressed as 
MV ± SD of triplicate determinations.  
(C) As in A, but in the presence of WIN52035-2 (5 µg/ml), an inhibitor of HRV-
receptor interaction. The Figure shows the result of one representative out of 
four independent experiments expressed as MV ± SD of triplicate 
determinations. 
 
R-DCs induced regulatory T cells are not correlated with a change in 
Foxp3 expression 
 
Foxp3 is a forkhead family transcription factor very importantly involved in the 
development of regulatory T cells (Tregs), therefore we evaluated its levels in 
R-DCs induced Tregs. Analysis of Foxp3 expression via quantitative PCR 
(qPCR) in CD25- T cells revealed that induction of Foxp3 does not differ 
between DC and R-DC stimulated T cells. This indicates that the suppressive 
capacity of R-DC stimulated T cells is not directly correlated with an increased 
induction of Foxp3. Also we have observed that Foxp3 levels drop again after 
48 h and 96 h in T cells stimulated with R-DC as well as DC (Figure 7). Such 
activation-induced transient Foxp3 expression in human T cells has been 
frequently observed before [43, 74, 75] and is not necessarily correlated with 
regulatory activity [43, 165, 169].  
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Figure 7. R-DC stimulated T cells are not correlated with an increased 
induction of Foxp3 
CD25- T cells were cocultured with DCs or R-DCs for the indicated timepoints 
and Foxp3 expression was evaluated via qPCR. The results of one 
representative experiment out of four independent experiments are shown. MV 
of duplicate determinations ± SD are shown; n.s. not significant. 
 
R-DCs induced peripheral blood regulatory T cells release an inhibitory 
factor 
 
In order to analyze whether the observed inhibitory effect was mediated through 
one ore more soluble factors, we added the supernatant (SN) of the R-DCs-
induced Tregs to T cell/DC cocultures. The SN of R-DCs alone, as described by 
us before, does not lead to diminished T cell proliferation [129].  
The inhibitory effect was however found in the SN of R-DCs-induced Tregs 
which is shown in Figure 8A, were the SN was added to an MLR. This indicates 
that a compound in the SN and not cell-cell contact establishes the inhibition of 
T cell proliferation.  
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To further define the nature of the T cells releasing this factor(s) we looked at 
CD4+ and CD8+ T cells separately. Either purified CD4+ or CD8+ peripheral 
blood T cells were cocultured with R-DCs and the SN of both, CD4+ as well as 
CD8+ T cells contained this suppressive factor (Figure 8B and C), because the 
SN of both again showed a strong T cell inhibitory capacity.  
This factor was not released by naïve T cells isolated from human cord blood, 
since the SN of naïve T cells cocultured with R-DCs was not inhibitory, as 
shown in Figure 8D.  
 
 
 
Figure 8. R-DCs induced Treg-cells release an inhibitory factor 
(A) Purified peripheral blood T cells were stimulated with DCs or R-DCs for 3 d. 
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The cell culture SN was harvested and examined in an allogeneic T cell DC 
coculture. DCs-triggered allogeneic T cell proliferation alone (○) or plus 100 µl 
SN from T cells preactivated with R-DCs (▲) or SN of T cells preactivated with 
mock-treated DCs (∆) is shown. The Figure shows the results of one 
representative experiment out of four independent experiments. MV of triplicate 
determinations ± SD are shown.  
(B) As in A, but the SN was derived from purified CD4+ T cells (▲ and ∆). The 
Figure shows the results of one representative experiment out of four 
independent experiments.  
(C) As in A, but the SN was derived from purified CD8+ T cells (▲ and ∆). The 
Figure shows the results of one representative experiment out of four 
independent experiments.  
(D) Purified naïve T cells isolated from human cord blood were stimulated with 
DCs or R-DCs for 3 d. The cell culture SN was harvested and examined in an 
allogeneic T cell DC coculture. DCs-triggered PB T cell proliferation alone (∆) or 
plus 100 µl SN from naïve T cells preactivated with R-DCs (■) or the SN of 
naïve T cells preactivated with mock-treated DCs (□) is shown. The Figure 
shows the results of one representative experiment out of four independent 
experiments. MV of triplicate determinations ± SD are shown. 
 
R-DCs do not inhibit proliferation of naïve T cells 
 
We than decided to take a closer look on naïve T cells isolated from human 
cord blood. These T cells, when cocultured with R-DCs did not show reduced 
proliferation (Figure 9B). This stands in contrast to the finding that in the 
coculture of peripheral blood T cells and R-DCs, T cell proliferation is impaired 
as described by Kirchberger et al. [129] and what we also reproduced in Figure 
9A. Thus, R-DCs mediated inhibition is specific for CD4+ and CD8+ effector T 
cells but not for naïve T cells isolated from human cord blood.  
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Figure 9. R-DCs do not inhibit naïve T cells 
(A) Purified peripheral blood T cells were stimulated with graded numbers of 
allogeneic DCs inoculated with HRV-14 (○) for 24 h, or mock-treated DCs 
(□).The results of one representative experiment out of four independent 
experiments are shown. MV of triplicate determinations ± SD are shown. 
(B) Purified naïve T cells isolated from human cord blood were stimulated with 
graded numbers of allogeneic DCs inoculated with HRV-14 (●) for 24 h, or 
mock-treated DCs (■). The results of one representative experiment out of three 
independent experiments are shown. MV of triplicate determinations ± SD are 
shown.  
 
R-DCs induced human regulatory T cells act independent of IL-10, TGF-ß 
and IFN-α  
 
One group of T cells with suppressor function are inducible Tregs. These cells 
can develop from mature T cell populations under certain conditions, e.g. upon 
stimulation with tolerogenic DCs. They act via release of soluble factors such as 
IL-10, a well established inhibitory molecule. IL-10 and TGF-ß, two cytokines 
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with suppressive capacity, can be released by inducible Tregs. Furthermore 
cultivation of T cells in the presence of type I IFNs and these two cytokines 
induces regulatory T cells [48]. 
In order to elucidate if the found inhibitory effect was mediated through IL-10 or 
other prominent inhibitory factors, we added the SN of our R-DCs-induced Treg-
cells to an MLR and investigated whether the inhibitory effect was reversible 
with neutralizing antibodies to IL-10, TGF-ß or IFN-α [44, 170].  
The inhibitory quality of the SN of R-DCs-induced Treg-cells was not reversible 
with mAbs against IL-10, IFN-α and TGF-β as depicted in Figure 10.  
 
 
 
 
Figure 10. The released inhibitory factor is not IL-10, TGF-ß or IFN-α 
Purified T cells were stimulated with DCs or R-DCs for 3 d. The cell culture SN 
was harvested and preincubated with neutralizing mAbs against IL-10, TGF-β 
and IFN-α (10 µg/ml) before examination in an allogeneic T cell proliferation 
response induced by DCs. Data are representative of 3 independent 
experiments. MV of triplicate determinations ± SD are shown.  
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The utilized mAbs against IL-10, TGF-β and IFN-α have neutralizing 
capacity 
 
To demonstrate that the utilized anti-cytokine Abs for Figure 10 were indeed 
neutralizing the following experiment was performed. First the inhibitory effect of 
IL-10, TGF-β and IFN-α on a T cell/DC coculture (MLR) was established and 
then the reversibility of this effect by adding the neutralizing respective 
antibodies was tested, this is depicted in Figure 11.  
 
 
 
Figure 11. The utilized mAbs have neutralizing capacity 
Proliferation of purified peripheral blood T cells (1x105) was induced with 
allogeneic DCs (1x104). IL-10, TGF-β or IFN-α (5 ng/ml) was added to the 
DCs/T cell coculture either alone or in combination with neutralizing mAbs (10 
µg/ml) against the respective factor. The results of one representative 
experiment out of three independent experiments are shown. MV of triplicate 
determinations ± SD are shown. 
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The released inhibitory factor is ≥ 50 kDa 
 
To determine the size range in which the inhibitory factor could be expected 
size fractionation of the T cell/R-DC SN was performed. It revealed that the 
inhibitory factor is found in the >50 kDa fraction and not in the <50 kDa 
molecular weight range (Figure 12).  
 
 
 
 
Figure 12. The released inhibitory factor is ≥ 50 kDa 
Purified T cells were stimulated with DCs or R-DCs for 3 d. The cell culture SN 
was harvested and size-fractionated. The inhibitory effect of the SN was found 
in the fraction ≥50 kDa (▲) and not in the fraction ≤50 kDa (■). Data are 
representative of 2 independent experiments. The results are expressed as MV 
± SD of triplicate determinations. 
 
 
R-DCs induce IL-35 expression in human T cells 
 
The observation that the inhibitory factor is expected to be >50 kDa lead us to 
investigate the recently described IL-35. IL-35 is a heterodimeric cytokine 
consisting of EBI3 (EBV-induced gene 3) and the p35 subunit of IL-12. It was 
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described to have inhibitory function, a molecular size of 78 kDa and to be 
produced by T cells [155].  
We observed that T cells cultured with R-DCs, showed elevated levels of EBI3 
and p35 mRNA, as shown by qPCR in Figure 13A. But there were no changes 
in the p28 levels, p28 forms together with EBI3 IL-27. Intracellular stainings 
showed that EBI3 was also upregulated at the protein level in peripheral blood T 
cells stimulated with R-DCs in comparison to T cells cocultured with DCs 
(Figure 13B, left column). In naïve T cells stimulated with R-DCs we did not 
observe an upregulation of EBI3 (Figure 13B, right column). P35 is 
constitutively expressed in DCs or R-DCs stimulated peripheral blood T cells or 
naïve T cells as shown in Figure 12B. This is in accordance to previous findings 
showing that p35 is constitutively expressed in various types of human T cells 
[164].  
In order to find out whether R-DCs induced inhibitory T cells release IL-35, we 
co-immunopreciptated the cytokine out of SNs of T cells and R-DCs or DCs co-
cultures, the supernatants were pooled from 6 donors. The cytokine was 
captured with an anti-p35 mAb coated on anti-mouse beads and than visualized 
with an anti-EBI3 Ab on the western blot membrane.  As shown in Figure 13C, 
R-DCs treated T cells release eminently more IL-35 as the DCs stimulated T 
cells.  
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Figure 13. R-DCs induce IL-35 expression, production and release in 
human T cells  
(A) T cells were cocultured with R-DCs (black bars) or DCs (white bars) in a 
10:1 ratio for 24 h and the production of EBI3, p35 and p28 was measured at 
the mRNA level via qPCR. One representative experiment out of three is 
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shown; MV ± SD are calculated from duplicates. 
(B) EBI3 and p35 production in peripheral blood (PB) T cells or naïve T cells 
isolated from human cord blood (CB) cocultured with DCs (open histogram) or 
R-DCs (filled histogram) for 24 h was detected by intracellular staining. The 
dotted line shows the isotype control mAb VIAP. The T cells gate is shown. 
Data are representative of three independent experiments.  
(C) Cell culture SN of T cells stimulated with DCs or R-DCs for 24-72 h were 
pooled from 6 independent experiments and immunoprecipitated with an 
antibody against p35. These samples were immunoblotted with an EBI3 
antibody (upper blot) or a control Ab: lower blot). As a loading control, the light 
chain of the p35 mAb used for precipitation, detected with sheep-anti–mouse-
HRP (SaM), was used. Blots were further analyzed densiometrically using 
Image J software. Data are presented as ratio of EBI3 protein to light chain. 
This experiment was performed three times and is representative of a pool of 6 
cell donors; p < 0.01 (**) and p < 0.001 (***). 
 
R-DCs induced inhibitory T cells do not release IL-12 and IL-27 
 
We wanted to control further, that no other cytokine of the IL-12 family was 
detected by our system. We excluded that IL-12 (which also has a p35 part) and 
IL-27 (sharing EBI3) were released by our R-DCs induced inhibitory T cells. 
First the anti-p35-mAb coated beads used for immuno-precipitation (previous 
Figure) of IL-35 out of the T cell/R-DC SN were analyzed via flow cytometry and 
show clear reactivity with the EBI3 antibody, confirming the release of IL-35, as 
depicted in Figure 14A. Only weak reactivity is observed with the respective 
beads precipitating out of the T cell/DC SN (Figure 14A). Moreover, you can 
see in Figure 14B only weak reactivity of the beads with anti-p40 mAb (IL-12) 
and no reactivity with anti-IL-27 mAb. This proves that T cells stimulated with R-
DCs do not release the IL-35 relatives: IL-12 and IL-27.  
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Figure 14. R-DCs induced inhibitory T cells do not release IL-12 and IL-27 
(A) Cell culture SN of T cells stimulated with DCs or R-DCs for 24-72 h were 
pooled from 6 independent experiments and immunoprecipitated with an 
antibody against p35. The anti-p35 coated beads left after precipitation were 
analyzed via flow cytometry. IL-35 was detected with an anti-EBI3 Ab. This 
experiment was performed once and is representative of a pool of 6 cell donors.  
(B) As in A but the IL-35 loaded anti-p35 coated beads were stained with anti-
IL-12p40 and anti-IL-27 mAb. This experiment was performed once and is 
representative of a pool of 6 cell donors. 
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The utilized antibody against EBI3 is specific for human EBI3 and IL-35 
 
EBI3 is a 34 kDa glycoprotein identified in B lymphocytes following EBV 
infection, it is homologous to the p40 subunit of IL-12. EBI3 gene expression is 
restricted to specific cell types (hematopoietic cells) and highly inducible.  
Results presented in Figure 15 show that the polyclonal anti-EBI3 Ab that was 
used throughout the study is specific for EBI3. It detects a band of correct size 
(34 kDa) in an EBV transfected cell line. These cells also could be stained with 
the anti EBI3 Ab (Figure 15A below). Also the Ab reacts with purchased 
recombinant IL-35:Fc in western blot analysis (also at the predicted protein size 
specified by distributer) as well as in flow cytometry (Figure 15B).  
Finally addition of recombinant IL-35:Fc to the EBV transfected cell line as well 
as to T cells deriving from a T cell/R-DC coculture, blocks the binding of the 
EBI3 antibody as shown in Figure 15C. 
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Figure 15. The utilized antibody against EBI3 binds human EBI3 and IL-35 
(A) The Daudi B cell line and an EBV transformed B cell line were analyzed via 
western blot and flow cytometry for their EBI3 expression. The results of one 
representative experiment out of three independent experiments are shown. 
(B) Purchased human IL-35:Fc was loaded on a gel and detected via western 
blot with the polyclonal anti-EBI3 Ab. Further a solution of IL-35:Fc (1 µg/ml) in 
medium was immunoprecipitated with anti-p35 coated beads or control Ab 
coated beads. The beads were analyzed via flow cytometry and IL-35:Fc was 
detected with an EBI3 antibody. The results of one representative experiment 
out of three independent experiments are shown.  
(C) IL-35:Fc (1 µg/ml) was added to the EBV cell line (upper blot) or a TC/R-DC 
coculture (lower blot) before staining. EBI3 expression was determined via 
intracellular staining. The results of one representative experiment out of three 
independent experiments are shown. 
 
PMA/Ionomycin activated T cells cocultured with R-DC express elevated 
levels of EBI3 and p35  
 
To test if additional T cell activation could alter the IL-35 release, we activated 
the T cells cocultured with DC or R-DC with PMA/Ionomycin for 12 h. T cells 
previously activated with R-DC additionally stimulated with PMA/Ionomycin 
showed a slight increase in p35 and EBI3 detected via flow cytometry, as 
shown in Figure 16. This is in comparison with the same cells activated only 
with R-DC. Resting PB T cells or T cells prestimulated with DC did not express 
IL-35 subunits upon PMA/Ionomycin stimulation.  
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Figure 16. T cells cocultured with R-DC express elevated levels of EBI3 
and p35 upon PMA/Ionomycin stimulation  
T cells cocultured with R-DCs for 3 days where activated with PMA/Ionomycin 
for 12 h, or left untreated. EBI3 and p35 expression detected by intracellular 
staining was analyzed via flow cytometry. The dotted line shows the isotype 
control mAb VIAP. One representative experiment out of three is shown. 
 
IL-35 contributes to the inhibitory function of R-DCs induced regulatory T 
cells 
 
As R-DCs-treated T cells display a regulatory phenotype and release IL-35, the 
following experiments were designed to examine whether the observed effects 
were mediated by this cytokine.  
We added the inhibitory SN of the R-DCs-induced Treg-cells to an allogeneic 
MLR together with a polyclonal antibody to EBI3 or a mAb against p35. We 
could show that the inhibitory effect of the SN from T cells was abolished and 
proliferation restored. Figure 17A and B illustrate that antibodies directed 
against both subunits were able to neutralize the inhibitory capacity of the T 
cell/R-DC SN. 
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Figure 17. IL-35 is responsible for the inhibitory effect  
(A) Purified T cells were stimulated with DCs or R-DCs for 2 days. The cell 
culture SN was harvested and examined in an allogeneic T cell DC coculture. 
The SN was preincubated with a neutralizing polyclonal Ab against EBI3 (10 
µg/ml / black bars) or a polyclonal isotype control (10 µg/ml / striped bars) or 
mock treated (white bars). T cell proliferation with allogeneic DCs (1x104) alone 
is depicted as a black circle. Data are representative of 5 independent 
experiments. MV of triplicate determinations ± SD are shown. 
(B) As in A with a neutralizing mAb against p35 (10 µg/ml / black bars) or an 
isotype control mAb VIAP (10 µg/ml / striped bars) or mock treated (white bars). 
Data are representative of 3 independent experiments. MV of triplicate 
determinations ± SD are shown. 
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Neutralizing IL-12 or IL-27 Abs do not alter the inhibitory function of the 
SN of the R-DCs-induced regulatory T
 
cells 
 
We added the inhibitory SN of the R-DCs-induced Treg-cells to an allogeneic 
MLR together with antibodies against IL-12p40 or IL-27. In comparison to the 
previous Figure these Abs did not alter the inhibitory function of the SN (Figure 
18A and B).  
 
 
 
 
 
Figure 18. Neutralizing IL-12 or IL-27 Abs do not alter the inhibitory 
function of the SN 
(A) Purified T cells were stimulated with DCs or R-DCs for 2 days. The cell 
culture SN was harvested and examined in an allogeneic T cell DC coculture. 
The SN was preincubated with a mAb against IL-12p40 (10 µg/ml / black bars) 
or an isotype control mAb VIAP (10 µg/ml / striped bars) or mock treated (white 
bars). Data are representative of 3 independent experiments. MV of triplicate 
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determinations ± SD are shown.  
(B) As in A with a mAb against IL-27 (10 µg/ml / black bars) or an isotype 
control mAb VIAP (10 µg/ml / striped bars) or mock treated (white bars). Data 
are representative of 3 independent experiments. MV of triplicate 
determinations ± SD are shown.  
 
The IL-35 depleted SN is no longer inhibitory  
 
We were able to precipitate IL-35 out of the SN of the T cell/R-DC coculture (as 
shown in Figure 13 and 14). Next we used the p35-depleted SN in an MLR. 
This SN was no longer inhibitory as depicted in Figure 19, whereas the T cell/R-
DC SN, precipitated with a control Ab or mock treated, was still inhibitory. Thus 
the inhibitory effect of R-DCs induced Tregs is mediated by IL-35.  
 
 
 
 
Figure 19. IL-35 depleted SN is no longer inhibitory 
The p35 depleted or with control Ab depleted SN left after precipitation (black 
and grey bars) were examined in an allogeneic T cell DC coculture in 
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comparison with the non depleted ones from the same donor pool (white bars). 
T cell proliferation with allogeneic DCs (1x104) alone is depicted as a black 
circle. Data are representative of three independent experiments. MV of 
triplicate determinations ± SD are shown;  
 
 
The same SN of a T cell/R-DC coculture, depleted with anti-IL-12p40 or anti-IL-
27 Abs was still inhibitory, when tested in an MLR (Figure 20A and B). We can 
thereby further exclude an involvement of these cytokines in the observed 
effects.  
 
 
 
 
Figure 20. IL-12 as well al Il-27 depleted SN is still inhibitory 
(A) Purified T cells were stimulated with DCs or R-DCs for 2 days. The cell 
culture SN was IL-12p40 depleted or with control Ab depleted and than 
examined in an allogeneic T cell DC coculture. Data are representative of three 
independent experiments. MV of triplicate determinations ± SD are shown.  
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(B) as in A but the SN was IL-27 depleted or with control Ab depleted. Data are 
representative of three independent experiments. MV of triplicate 
determinations ± SD are shown. p<0.001 (***). 
 
 
Next we checked as a control for the above results, if we were able to 
precipitate recombinant IL-12 with the utilized anti-p40 mAb. As you can see in 
Figure 21, this is the case. The mAb was used in Figure 20 to check if removal 
of possible IL-12 present in the inhibitory SN could change the outcome of the 
experiment.  
 
 
 
Figure 21. The utilized antibody against IL-12p40 can precipitate 
recombinant human IL-12  
A solution of recombinant human IL-12 (1 µg/ml) in medium was 
immunoprecipitated with anti-p40 coated beads. The beads were analyzed via 
flow cytometry and IL-12 was detected with a p35 and p70 antibody, or isotype 
control VIAP. The results of one representative experiment out of two 
independent experiments are shown.  
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CD4+ as well as CD8+ T cells produce EBI3 and p35 upon stimulation with 
R-DC 
 
There are two major subsets of T cells that differ in effector function, MHC 
restriction and accessory molecule usage, namely the CD4 (T helper cells) and 
the CD8 (cytotoxic T cell) positive subset of T cells.  
We repeated some of the so far performed experiments with purified CD4+ and 
CD8+ T cells, to clarify if we could produce the observed effects with each cell 
type. We have already shown in Fgure 8, that both T cell subsets are able to 
produce the inhibitory SN.  
Both subsets gain regulatory function upon stimulation with R-DC (Figure 22A), 
express EBI3 and p35 as shown by flow cytometry (Figure 22B) and qPCR 
(Figure 22 C). Also the inhibitory effect of the SN can be reverted by antibodies 
against IL-35 (EBI3 and p35; Figure 22D). This indicates that both subsets can 
produce IL-35.  
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Figure 22. CD4+ and CD8+ T cells produce EBI3 and p35 upon stimulation 
with R-DC 
(A) Human purified T cells (1x105) were stimulated with allogeneic DCs (1x104) 
alone (●) or in the presence of graded numbers of CD4+ or CD8+ T cells, which 
had been preactivated with R-DCs (▲) or mock treated DCs (■). The Figure 
shows the result of one representative out of three independent experiments. 
(B) EBI3 and p35 production in peripheral blood CD4+ or CD8+ T cells 
cocultured with DCs (open histogram) or R-DCs (filled histogram) for 24 h was 
detected by intracellular staining. The dotted line shows the isotype control mAb 
VIAP. Data are representative of three independent experiments.  
(C) CD4+ or CD8+ T cells were cocultured with R-DCs (black bars) or DCs 
(white bars) in a 10:1 ratio for 24 h and the production of EBI3 was measured at 
the mRNA level via qPCR. One representative experiment out of three is 
shown, MV ± SD are calculated from duplicates.  
(D) CD4+ or CD8+ Purified T cells were stimulated with DCs or R-DCs for 2 
days. The cell culture SN was harvested and examined in an allogeneic MLR. 
The SN was preincubated with an Ab against EBI3 (10 µg/ml / black bars) or a 
mAb against p35 (10 µg/ml striped bars) or mock treated (white bars). Data are 
representative of 5 independent experiments. MV of triplicate determinations ± 
SD are shown. 
 
B7-H1 and sialoadhesin on R-DCs induce the production of IL-35 
 
We have recently found that R-DC work via B7-H1 and sialoadhesin. Blocking 
of the accessory molecules B7-H1 and sialoadhesin on R-DCs with specific 
mAbs against both receptors reverted the inhibitory phenotype of R-DCs [129].  
Neutralizing antibodies to B7-H1 and sialoadhesin were added to the T cell/R-
DCs coculture. The production of EBI3 and therefore the production of IL-35 
could be effectively blocked by a combination of the two mAbs as presented in 
Figure 23. P35 expression did not change considerably with addition of the 
neutralizing antibodies (Figure 23A right column).  
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Figure 23. Blocking of B7-H1 and Sialoadhesin on R-DCs prevents the 
production of IL-35  
T cells were cocultured with R-DCs or DCs in a 10:1 ratio for 24 h in the 
presence of blocking antibodies (10 µg/ml) to B7-H1 (5-272) and sialoadhesin 
(7-239), or mock treated. EBI3 and p35 production was evaluated by 
intracellular staining (filled histograms). The black line shows the isotype control 
mAb VIAP. The T cell gate is shown in the histograms. Data are representative 
of two independent experiments.  
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The neutralizing antibodies were added also to a T cell/R-DC coculture and the 
cell culture SN of these cells (without Abs) was able to inhibit T cell proliferation. 
The antibodies alone partially reverted the inhibitory effect. By using a 
combination of both antibodies, proliferation could be restored, this is shown in 
Figure 24.  
Thus, the cell surface structures sialoadhesin and B7-H1 are involved in the 
induction of the IL-35+-Treg-cells. 
 
 
 
Figure 24. Blocking of B7-H1 and Sialoadhesin circumvents the inhibitory 
quality of the IL-35+ regulatory T cells 
 Purified T cells were stimulated with R-DCs for 2 days in the presence of 
blocking mAbs (10 µg/ml) to B7-H1 (5-272), sialoadhesin (7-239), both mAbs or 
mock treated. The cell culture SN was harvested and examined in the 
allogeneic T cell proliferation response induced by DCs. The Figure shows the 
results of one representative experiment of two independent experiments. MV 
of triplicate determinations ± SD are shown; p < 0.05 (*), p < 0.01 (**) and 
p<0.001 (***). 
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Discussion  
 
We demonstrate in this study that IL-35 production and release is induced in 
human peripheral blood CD4+ and CD8+ T cells, upon B7-H1 and sialoadhesin 
co-stimulation provided by DCs. Such IL-35+-T cells are potent Tregs, which, in 
contrast to IL-10-driven type-1 regulatory T cells (Tr1), do not suppress T cell 
responses via IL-10 and/or TGF-β [44, 39], but via IL-35. Similar to the Tr1 
situation, also in our setting the supernatant of the IL-35+-T cells alone is 
sufficient to inhibit DC driven T cell proliferation. Several pieces of evidence 
support the conclusion that the R-DCs induced Tregs act through IL-35. 
Neutralization with anti-EBI3 and anti-p35 antibodies as well as depletion of IL-
35 removed the inhibitory effect of the SN of Tregs. Naïve T cells from cord 
blood, which do not produce IL-35 upon stimulation with R-DCs, lack 
suppressor function. Thus, induction of IL-35 represents a novel activation 
program in human T cells in response to viral infection.  
EBV-induced gene 3 (EBI3) is a member of the IL-12 family that was first 
identified in B lymphocytes based on its induction following EBV infection. It 
codes for a 34 kDa-secreted glycoprotein homologous to the p40 subunit of IL-
12. Recent studies have shown that EBI3 can dimerize with IL-12 p35 and 
EBI3/p35 was called IL-35 [155, 160]. Data presented in Figure 17 and 19 
demonstrate that IL-35 and not the other related cytokines IL-27 or even IL-12 
are responsible for the inhibitory effect of the supernatant, that was observed in 
our study.  
The first critical step in how HRV alters DC function is binding to its cellular 
receptor ICAM-1 (CD54). To exclude that HRV is transferred from the R-DC to 
the T cells we added the specific inhibitor WIN 52035-2 to the co-culture after 
the R-DC generation. WIN 52035-2 blocks HRV binding to ICAM-1 [168]. Even 
though this reagent was present the R-DCs were still able to introduce the 
regulatory phenotype in the T cells, showing that viral transfer and infection of T 
cells with HRV does not play a role in IL-35 generation. This data is given in 
Figure 6C.  
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The data of this study demonstrate for the first time that IL-35 is a potent 
regulatory cytokine also in the human immune system. This works through a 
combinatorial signal delivered from DCs to T cells via the accessory molecules 
B7-H1 and sialoadhesin. This signal is critical for the induction of human IL-35+ 
regulatory T cells (Figure 25).  
 
As we have already shown before HRV inhibit the accessory function of DCs by 
inducing sialoadhesin and B7-H1 expression [129]. This shows that DCs not 
only efficiently stimulate T cell activation, but can also regulate T cell responses. 
B7-H1, a member of the B7-molecule family, is a well-defined accessory 
molecule with inhibitory effects through its receptor PD-1 on the T cell side [130, 
171]. We and other groups have recently demonstrated that B7-H1 is critically 
involved in the induction and maintenance of T cell anergy [131]. There is 
abundant evidence that different viruses abuse B7-H1 to turn-off effector T cell 
responses [172-174]. The findings of this study imply that B7-H1-mediated 
inhibition of T cell responses is at least in part due to its property to contribute to 
the induction of IL-35 production. Yet, B7-H1 alone was not sufficient to induce 
IL-35, but required co-signaling via sialoadhesin. Sialoadhesin is a member of 
sialic acid binding lectin family of I-type lectins, which preferentially bind to 
sialylated carbohydrate structures (e.g. NeuAcα2,3-Gal) [132] and CD43 has 
been recently described as a ligand for sialoadhesin on T cells [133]. 
Sialoadhesin is a frequently used marker for macrophages because it is 
typically not expressed on monocytes, lymphocytes and DCs. Yet, type-I IFNs 
have been recently reported to up-regulate sialoadhesin on monocytes [133, 
175-177] but also on DCs (C. Schrauf, unpublished observation). Thus, sensing 
of viral infections by DCs leads to the up-regulation of the inhibitory receptor 
pair B7-H1 and sialoadhesin, this is critical for the induction of IL-35+ Treg-cells. 
 
The IL-12 cytokine family, which is related to the IL-6 cytokine family, is of great 
importance and includes IL-12, IL-23, IL-27 and the newest member IL-35. All 
four are heterodimeric cytokines, composed of an alpha chain (p19, p28, or 
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p35) and a beta chain (p40 or Ebi3). IL-12, IL-23 and IL-27 signal through 
unique pairings of five receptor chains (IL-12Rb1, IL-12Rb2, IL-23R, gp130 and 
WSX-1) [161]. The potential receptor or receptors for IL-35 have not been 
defined so far, neither for the murine nor the human system. But one can 
strongly speculate that they could consist of the already identified receptors for 
other members of the IL-12 family. All other IL-12 family members signal 
through dimeric receptors followed by intracellular signaling using the 
phosphorylation of JAK, followed by STAT family member activation [167]. IL-
12, was first described in 1991 [178] and provided the first insight into the 
extensive chain sharing that has become a characteristic of this cytokine family. 
Over 10 years ago, a second ß chain, EBI3, was identified. The p35 chain of IL-
12 signals through the IL-12-receptor ß2 chain and the EBI3 part of IL-27 either 
signals via gp130 (CD130, IL-6 receptor ß) or via WSX-1 (IL-27R, TCCR) [161]. 
The p35 subunit of IL-12 binds to IL-12-receptor ß2 chain therefore this may be 
a chain of the putative IL-35 receptor. IL-27 signaling requires WSX-1 as well as 
gp130; however, direct binding studies to determine which subunit of IL-27 
interacts with the individual receptor chains have not been performed yet. 
Therefore, it is possible that either WSX-1 or gp130 may be members of the IL-
35 receptor. Whether IL-35 signals through a dimeric receptor or not and 
whether this receptor is composed of already known modules has not been 
defined yet, also the nature of the signalling cascade it initiates remains to be 
determined.  
Although chain as well as receptor sharing is important in the IL-12 cytokine 
family, there is still also the possibility that IL-35 binds to a completely unknown 
receptor. A hint for this would be that all the other members of the IL-12 family 
have rather immune-stimulatory effects, in contrast to IL-35. They activate 
different subsets of T cells and are produced by APCs, mainly DCs, following 
their activation via the recognition of pathogen specific patterns [161]. IL-35 for 
that matter is produced by T cells and seems to have opposing effects; it acts 
on T cells in an immune-inhibitory manner. While IL-12, IL-23, and IL-27 share 
the common feature of inducing IFN-gamma production and promoting Th1 cell 
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differentiation and proliferation, IL-35 appears to function in an anti-
inflammatory fashion by inhibiting T cell proliferation and perhaps other 
parameters [155, 160].  
Understanding the unique features of IL-12, IL-23, IL-27, and IL-35 and 
potential synergy and/or competition between the members of the IL-12 
cytokine family is of great importance, and many further studies in this direction 
are necessary. Significant insight is likely to be gained from the determination of 
the IL-35 receptor and its expression pattern. 
 
 
 
Figure 25. Summary 
Upregulation of the surface structures B7-H1 and sialoadhesin on HRV treated 
DCs leads to the induction of IL-35 producing T cells. IL-35 then has an 
inhibitory effect on other T cells, via so far undefined mechanisms.  
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IL-35 is composed of two chains, which it shares with two other heterodimeric 
cytokines. IL-35 is required for maximal regulatory function in vivo in the mouse 
as Tregs deficient in either chain are unable to control homeostatic T cell 
expansion and inflammatoty bowel disease (IBD) [160]. Given that IL-35 has 
been described more recently, we still have a limited understanding of its 
biological activity, which has also been complicated by the lack of appropriate 
tools for its functional dissection. At the moment for example there is no ELISA 
or even Ab commercially available that detects IL-35. Recombinant IL-35 as 
well has proven particularly challenging to generate and purify according to the 
review of Vignalli and Bettini [179]. They speculate that the apparent poor 
stability of IL-35 might underlie important physiological features of this cytokine, 
such as limited potency over short-range. Alternatively, DCs that secrete IL-12 
or IL-27 may be precluded from generating IL-35, because of preferential 
pairing of IL-12 and IL-27. It is clearly important to determine the bioactivity of 
IL-35. Whether IL-35 can inhibit all Th subsets and other cellular populations, 
such as B cells, macrophages or DCs, or has more selective targets also 
remains to be determined.  
 
The in vivo association between EBI3 and p35 was originally evidenced in 
human placental extracts, the group describing this was able to co-precipitate 
EBI3 and p35 [166], similar as in this study. EBI3 and p35 are highly expressed 
in placental trophoblasts, which suggests that IL-35 may be an 
immunomodulator at the feto-maternal border. Trophoblasts have been thought 
to be key players in maternal tolerance to the fetus, and that they accomplish 
that in part by cytokine production [180]. They are at the frontier between the 
placenta and the potentially immunologically hostile environment of the uterus. 
IL-35 seems to be of importance in situations were immuno-suppression is 
needed, like during pregnancy. Already in this early study from 1997 [166] is 
was speculated that IL-35 (although at that time it was calles EBI3/p35 
heterodimer) is likely to antagonize the biological effects of IL-12. What this 
early studies also showed is that EBI3 can be expressed at high levels not only 
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in placental trophoblast cells but also in activated DCs, human B lymphoblast 
cells, tonsils and spleen [158, 166].  
More recent studies demonstrated that IL-35 is constitutively expressed by 
mouse CD4+CD25+Foxp3+ Tregs [155, 160]. In the murine system IL-35 is a 
downstream target of Foxp3 [160]. Transcripts coding for EBI3 and p35 were 
observed to be constitutively coexpressed by mouse Tregs and EBI3/p35 
heterodimer was coprecipitated from the cell culture supernatant of these cells. 
In addition, in vitro and in vivo studies suggested that the expression of IL-35 by 
mouse Tregs contributed to their suppressive function [161]. EBI3 alone is not 
immunosuppressive [155]. Recombinant mouse IL-35 was shown to inhibit the 
proliferation of mouse effector T cells in vitro. In another recent study, a single 
chain mouse IL-35-Fc fusion protein was able to enhance the proliferation of 
mouse Treg-cells, while inhibiting the development of Th17 cells [155].  
However, human CD4+CD25+Foxp3+ regulatory T cells do not constitutively 
express IL-35 and induction of Foxp3 does neither upregulate EBI3 nor p35 
mRNA in human T cells. Nevertheless EBI3 transcripts are found in activated 
effector CD3 positive T cells and p35 is described to be constitutively expressed 
in various T cell subsets. [164, 165]. These findings do not contradict ours; the 
IL-35 producing T cell population that we describe does not have the 
CD4+CD25+Foxp3+ natural regulatory T cell phenotype, but is a new, so far un-
described adaptive T cell subset. Its regulatory phenotype is induced by R-DCs. 
One interesting feature of R-DCs is that the expression of most costimulatory 
molecules analyzed was not affected on their surface [129]. For instance, CD40, 
CD58, CD80, and CD86 expression was similar on R-DCs and on untreated 
DCs. Likewise, expression of MHC class I and class II molecules, was not 
down-regulated on R-DC. Thus, the clearly reduced T cell stimulatory capacity 
of R-DC did not correlate with a reduced ability to deliver signal 1 and 2 to T 
cells. Knowing this, we could speculate that R-DC co-cultured T cells (despite 
their anergy) could actually be activated in a way by the R-DCs, to obtain their 
IL-35 producing phenotype. This fits well to the findings of Bardel et al. [164], 
that EBI3 expression in humans is found in the activated T cell population. Also 
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conventional CD4+CD25+Foxp3+ natural Treg-cells need to be activated via 
their TCR to become fully potent suppressors [35].  
We observe transient Foxp3 expression in T cells stimulated with R-DC as well 
as DC. Such temporal activation-induced Foxp3 expression in human T cells 
has been described before for effector T cells as well as for Tr1 cells and is not 
obligatory correlated with regulatory function, whereas natural CD4+CD25+ 
regulatory T cells show constitutive high Foxp3 expression [43, 68]. The sole 
use of Foxp3 expression to determine if a human T cell has regulatory function 
has been questioned, and this molecule no longer seems to be the master 
regulator for Tregs in humans. Foxp3 expression is for instance not a 
prerequisite for Tr1 cells, and we can show here that it is also seems not to be 
necessary for IL-35 producing T cells.  
 
The expression of EBI3 and p35 is up-regulated in T cells stimulated with R-
DCs and also in T cells stimulated with DCs which were activated with IFN-α 
(diplma thesis S.Zeiner), suggesting that other viral stimuli could also trigger IL-
35. Also, since induction of B7-H1 and sialoadhesin expression on DC seems to 
be induced by many other viruses as well, it is intriguing to suggest that 
induction of IL-35+ Treg-cells is a general theme in viral infections. 
Because of their importance in initiating antiviral immune responses, DCs 
represent an ideal target for viral immune-evasion strategies. Several viruses 
are known to modulate DC function and thus impair antiviral T cell responses 
[181]. We have discovered a novel pathway of immune-regulation by analyzing 
the impact of HRV on DCs. HRV are specialized pathogens and only infect 
humans with all the well-known symptoms of a cold. HRV infection is probably 
the most frequent human infectious disease, which indicates that the host/HRV 
relationship is highly evolved. HRV utilizes a variety of tricks to blunt our 
immune-system [123] and induction of IL-35+ Treg-cells may represent another 
prominent immune-evasion mechanism.  
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Material and Methods 
 
Antibodies 
 
The following murine mAbs were generated in our laboratory: negative control 
antibody VIAP (against calf intestine alkaline phosphatase), 5-272 (B7-H1), 7-
239 (CD169, sialoadhesin), VIT6b (CD1a). The polyclonal murine antibodies 
against EBI3 and GNAI2 (guanine nucleotide binding protein, alpha inhibiting 
activity polypeptide 2; used as isotype control for EBI3) were purchased from 
Abnova Corporation (Taipei, Taiwan).  
The monoclonal antibodies against p35 (clone27537), IL-12p40 (mAb609), IL-
12p70 (mAb611), IL-27 (mAb25261) and TGF-β (mAb240) were purchased 
from R&D Systems Inc. (Minneapolis, MN). The neutralizing polyclonal anti–IL-
10 antibody (PAL-hIL10) was obtained from Strathmann Biotech (Hannover, 
Germany). MAb EB-I against IFN-α was kindly provided by G. Adolf (Boehringer 
Ingelheim). 
 
Cells 
 
Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
 
PBMCs were isolated from buffy coats obtained from the Red Cross in Austria. 
PBMNC were separated from whole blood of healthy donors by density gradient 
centrifugation using Ficoll-Paque (GE Healthcare, London, UK). Blood was 
diluted 1:2 to 1:3 with heparin-medium. For density gradient centrifugation 15 ml 
of Ficoll-Paque were prepared in 50 ml tubes and a layer of heparinized blood 
was carefully pipetted onto. The cells were spun 30 minutes at 900 g without 
brake. After centrifugation granulocytes and erythrocytes gathered at the bottom 
of the tube, peripheral blood mononuclear cells in the interphase. The white 
interphase ring was transferred into a new tube and spun down (5 minutes at 
900 g). The supernatant was discarded. The cells were washed twice with 
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MACS-buffer: The pellet was resuspend in a few ml of buffer, filled up, spun 
down. The supernatant was discarded, and the cells again resuspend. The 
number of PBMCs was determined and the cells were used for monocyte and T 
cell isolation. 
 
Magnetic cell sorting (MACS)  
 
Magnetic cell sorting (MACS) is a method for the selective enrichment or 
depletion of cells which express a surface protein distinct for their cell type. 
Therefore cells can be labelled with antibodies directed against the specific 
molecule which have been coupled to biotin. These labelled cells can be 
targeted with magnetic beads that contain a secondary antibody directed 
against the biotin residues on the primary antibody. Therefore specific cells in a 
mixture can be selectively retained in a magnetic column.  
The mAbs we used were labelled with biotin. These biotinylated antibodies 
recognizing cell-type specific surface molecules were mixed with the cells to be 
separated. Then the cells were washed twice with MACS-buffer. In a second 
incubation step paramagnetic beads (50 nm in diameter) were coupled to the 
cells. The cells were applied onto a separation column placed in a strong 
permanent magnet. In this strong magnetic field the cells labelled with 
paramagnetic beads stack to the iron mesh and were retained while non-
labelled cells passed through. Retained cells were eluted by removing the 
column from the magnetic field.  
 
Isolation of monocytes and T cells from peripheral blood  
 
Freshly isolated PBMCs were resuspended in 750 µl MACS buffer and 
incubated with 250 µl biotinylated antibodies for 15 minutes at 4 °C. To remove 
unbound antibodies the cells were washed with MACS buffer and again 
resuspended in 750 µl buffer. Then 250 µl anti-Streptavidin MicroBeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) were added to the suspension 
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and incubated for 15 minutes at 4°C. In the mean time a CS column (Miltenyi 
Biotec) was placed onto a VarioMACS apparatus and equilibrated with 40 ml 
MACS buffer. Afterwards the labelled PBMCs were loaded onto the column and 
for monocyte enrichment washed with 40 ml MACS buffer. The flow through 
was collected as monocyte negative fraction. The column was further washed 4 
times with 10 ml MACS buffer and monocytes were collected by removal of the 
column from the magnet and aspiration of the retained cells from the side valve 
using a syringe.  
Monocytes were positively selected by magnetic cell sorting from PBMCs. For 
the selection we used the monocyte marker CD14 (mAb: VIM13: 15 µg/ml & 
MEM18: 15 µg/ml) produced in our laboratory. For the isolation of monocytes up 
to 1 x 109 PBMCs were incubated with 250 µl of biotinylated CD14 and 
positively enriched (positive selection). 
T cells were isolated by collecting the flowthrough of PBMCs depleted by using 
an antibody cocktail containing anti-CD14 (monocytes), anti-CD16 (monocytes, 
NK–cells), anti-CD19 (B cells), anti-CD36 (monocytes, thrombocytes), anti-
CD56 (NK-cells) and anti-CD123 (progenitor cells, megakaryocytes, 
granulocytes, negative selection). For T cells the flowthrough was collected, 
washed with MACS buffer and counted. 20 µl of this solution were pipetted into 
a tube for cell counting with the coulter. Before measuring the cell number two 
drops of Zap-Oglobin® (Beckman Coulter, Miami, FL) are added to remove 
residual erythrocytes. 
The purity of monocytes and T cells was controlled by immunofluorescence 
analysis. Double-staining with directly labelled Antibodies using: CD14-
PE/CD45-FITC; CD19-PE/CD3-FITC, CD8-PE/CD4-FITC, HLA-DR-PE/CD3-
FITC, CD56-PE/CD3-FITC, CD14-PE/HLA-DR-FITC. 
 
Isolation of naïve T cells from human cord blood 
 
Naive T cells were isolated from cord blood as described above. Cord blood 
samples from healthy donors were collected during healthy full-term deliveries. 
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Approval was obtained from the Medical University of Vienna institutional review 
board for these studies. Cord blood T cells used in this study were CD45RA+ 
(92 ±3%) and CD45RO–. 
 
Cell Culture conditions 
 
For cell culture RPMI 1640 (Gibco Ltd., Paisley, Scotland) supplemented with 
10% FCS (Sigma-Aldrich, St. Louis, MO), 2 mM L-glutamine (Sigma-Aldrich), 
100 U/ml penicillin and 100 µg/ml streptamycin (Sigma-Aldrich) was used. Cells 
were cultured at 37°C with 5% CO2. 
 
Freezing and thawing of cells 
 
Mammalian cells can be stored in liquid nitrogen for prolonged periods of time 
with minimal loss of viability. For that purpose, cells were spun down, counted 
and resuspended in freezing medium to a concentration between 107 – 5 x 107 
cells/ml. 1 ml aliquots were filled into cryotubes (Nalge Nunc International, 
Roskilde, Denmark) and kept overnight at - 80°C in a freezing box filled with 
isopropanol before being transferred to liquid nitrogen. 
Cryotubes were thawed in a 37 °C warm water bath until all frozen media was 
dissolved. Cells were washed two times with RPMI Media (Gibco Ltd., Paisley, 
Scotland) resuspended in RPMI 10% FCS supplemented L-glutamine, penicillin 
and streptamycin and further cultured. 
 
Generation of monocyte-derived DC 
 
Monocyte-derived immature dendritic cells were generated by culturing 
peripheral blood CD14+ monocytes for 7 days in the presence of 50 ng/ml GM-
CSF (Novartis Research Institute, Vienna) and 100 U/ml IL-4 (Novartis 
Research Institute, Vienna). 
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Preparation and purification of Rhinoviruses – Generation of R-DC 
 
HRV-14 was obtained from American Type Culture Collection (ATCC, 
Manassas, VA) and routinely grown in suspension cultures of HeLa cells (strain 
Ohio; Flow Laboratories, McLean, Virginia, USA). Cells were cultivated in S-
MEM medium (Joklik modification; catalog no. 22300-107; Life Technologies 
Inc., Rockville, Maryland, USA) supplemented with 7% heat-inactivated horse 
serum (catalog number 01051-M; Diagnostic Products GesmbLT, Wiener 
Neudorf, Austria), 1% penicillin/streptomycin, 1% glutamine, 1% pluronic F68 
(catalog no. P1300; Sigma Chemical Co., St. Louis, Missouri, USA), and 1% 
nonessential amino acids.  
To obtain HRV-14 treated DCs (R-DC), immature DCs were cultured with 1 
TCID50 (50% tissue culture infectious dose) HRV-14 for 2 days. 
 
Allogeneic Mixed Leukocyte Reaction (Allo-MLR) 
 
Lymphocytes from one donor are mixed with stimulator cells from another. If the 
two cell populations are not compatible in their MHC, which means they are 
allogeneic, proliferation of T cells occurs. In our experiments we measured the 
capacity of T cells preactivated with HRV-treated and untreated DCs to induce 
T cell proliferation in an MLR. We also investigated the influence of different 
supernatants (SN) on T cell proliferation in an MLR and also added specific 
antibodies wherever mentioned. The expansion of T cells was determined by 
measuring the methyl-3H-thymidine incorporation into the DNA.  
Stimulator cells (DC) from a different donor as the T cells used were cultivated 
as described before. On day 7 the DCs were harvested: spun down for 5 
minutes at 300 g, the supernatant was discarded, the cells were resuspend and 
counted. Finally the cell number was adjusted to 1x106 cells/ml. In most assays 
the concentration of stimulator cells used was 1x104 cells/well.  
Frozen T cells were thawed as described before. There cell number was 
adjusted to 1x106 cells/ml. For the MLR, allogeneic, purified T cells (1x105) were 
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incubated with DCs. The experiments were performed in a 96 well U-bottom cell 
culture plate plates (Packard, Meriden, Connecticut), in triplets. Generally we 
added 100 µl of T cells to each well i.e. 100.000 cells/well. The MLR-assay was 
incubated for 5 days at 37°C 5% CO2 . 
For Figure 6 pre-activated T cells were harvested, irradiated (30 Gy, 137Cs 
source) and tested for their suppressive function, for Figure 9 pre-activated T 
cells were not irradiated. For that purposes, increasing numbers of pre-activated 
T cells were added to an allogeneic MLR with a fixed number of T cells (1x105) 
and DCs (1x104).  
To quantify the extend of the T cell proliferation we measured the incorporation 
of methyl-3H-thymidine into the DNA. On the fourth day of cultivation 25µl of 
methyl-3H-thymidine 1mCi/ml (Perkin Elmer, Waltham, MA) were added to each 
well. 18 hours later (incubation at 37°C 5% CO2 ) the cells were harvested, by 
transferring the radioactively labelled DNA to Unifilter 96 plates using a Plate 
Harvester. The filter plates (Milipore Corp., Bedford, MA) were dried for 1hour at 
37°C, an a sticker was pressed to the bottom side, 25 µl of Microscint 
scintillation mix (Packard, Meriden, Connecticut) were added in each well and 
the plate was covered by an adhesive seal. Radioactivity was determined using 
a microplate scintillation counter (Packard). 
 
The HRV-blocking reagent WIN 52035-2 [168] was a kind gift from the Sterling-
Winthrop Research Institute (Rensselaer, NY) and was used at a final 
concentration of 5 µg/ml, to exclude the possibility of viral transfer.  
 
All the antibodies used in the allo-MLRs for neutralization were diluted with cell 
culture medium to a concentration of 10 µg/ml. To prove that neutralization 
worked, recombinant human IL-10, IFN-α, TGF-β were used at 5 ng/ml. IL-10, 
TGF-β and IL-12 were purchased from R&D Systems Inc. (Minneapolis, MN). 
IFN-α (isoform 2c) was purchased from Boehringer Ingelheim (Vienna, Austria).  
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 T cell – DC / supernatant generation 
 
To examine the suppressor activity of the SN of R-DCs-induced Treg-cells, T 
cells were added to R-DCs or DCs in a 10:1 or 5:1 / T cell to DC ratio. These 
SNs were harvested after 1-3 days of coculture and 100 µl/well were added to 
different MLRs. Or the SN was used for other purposes, like precipitation. 
Centricon YM-50 filters (Millipore) were used for size fractionation of the SN. 
The fraction containing molecules > 50 kDa was compared to the fraction 
containing molecules < 50 kDa in an allogeneic MLR.  
The T cells of the coculture were also investigated by intracellular staining or 
analyzed via qPCR (both described below). 
 
Flow cytometry 
 
Flow cytometry can be used to examine diverse properties of cells including the 
relative size, relative granularity and relative fluorescence intensity. Cells are 
transported in a fluid stream to a laser beam. To accomplish that single cells are 
passing through the beam, a principle related to laminar flow is applied. The 
sample is injected into a stream of sheath fluid. Cells within this stream are 
accelerated and are focused to the center, a process called hydrodynamic 
focussing.  
The incident laser light is scattered by the cells and detected in different angles. 
Forward scatter light (FSC) is measured just of the axis of the incident beam by 
a photo diode and gives information about the size of a particle. Side scatter 
light (SSC) is collected by a photo-multiplier at approximately 90° of the laser 
beam axis and is proportional to the granularity.  
The argon ion laser used emits light at 488 nm, a wavelength matching with the 
absorption spectrum of a range of fluorescent dyes. These fluorochromes can 
be excited by the laser, which means that an electron is raised to a higher state 
of energy. After returning to ground state a photon is emitted and fluorescence 
can be detected after passing a system of lenses and filters. The intensities of 
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different fluorochromes can be analysed at once, provided that their absorption 
maximae are not to close to each other.  
 
Immunofluorescence of cytoplasmic proteins 
 
Cells were incubated for 12 h in presence of monensin (10 µM, Sigma-Aldrich) 
that impairs further secretion of proteins, were mentioned also PMA and 
Ionomycin (both Sigma-Aldrich) was added (both 100 nM). 50 µl of cell 
suspension were mixed with 100 µl fixation medium (Bio Research GmbH, An 
der Grub, Kaumberg, Austria) and incubated for 20 minutes at room 
temperature. 100 µl permeabilisation medium (Bio Research GmbH, An der 
Grub) and 20 µl mAb were mixed and incubated 20 minutes at room 
temperature.  
The cells were washed with PBS def; spun for 5 minutes at 300 g, the 
supernatant was discarded. 50 µl permeabilisation medium and 20 µl of Oregon 
Green-conjugated goat-anti mouse Ig Abs from Invitrogen (Carlsbad, CA) mixed 
and incubated for 20 minutes at room temperature. 
The cells were washed twice with PBS def., spun for 5 minutes at 300 g. 
Samples were prepared for immunofluorescence analysis by addition of 50 µl of 
sheath fluid. Flow cytometric analysis was performed using a FACScalibur flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ).  
 
Immunoprecipitation, cytokine depletion and Western blotting 
 
Preparation of Dyna-beads 
 
500 µl of sheep anti-mouse IgG coupled Dynabeads (Dynal, Oslo, Norway) with 
2,8 µm diameter were washed twice with PBS def 1x using the Dynal magnet. 
The beads were mixed with 100 µl of murine antibody and incubated gently 
rotating for 1h. The antibody loaded beads were washed three times to get rid 
of unbound antibody.  
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Immunoprecipitation and cytokine depletion 
 
For immunoprecipitation mAbs p35, p40 or IL-27 (all R&D Systems Inc.) or mAb 
VIAP (isotype control) was loaded onto 7x107 sheep anti-mouse IgG coupled 
Dynabeads (Dynal, Oslo, Norway) with 2,8 µm diameter as described in detail 
above. Then the Ab coupled beads were incubated with the pooled cell-culture 
SNs (of a T cell/DC or T cell/R-DC coculture from six independent donors) for 
12 h at 4°C on a rotator. The beads were spun down and the SN of the beads 
was considered depleted of p35, p40 or IL-27 and tested in an MLR.  
The beads themselves were washed three times with cold PBS def 1x using the 
Dynal magnet and a part of the beads (2x106) was analyzed via flow cytometry. 
Therefore beads were incubated for 30 minutes at 4°C with unconjugated Abs 
against EBI3, IL-12p40, IL-27 or isotype control. After washing, Oregon Green-
conjugated goat anti–mouse-Ig from Invitrogen was used as a second-step 
reagent. Flow cytometric analysis was performed using a FACScalibur flow 
cytometer (BD Biosciences).  
Concerning the rest of the beads; bound protein was eluted with reducing 
sample buffer (100-200 µl / Biorad, Richmond, CA) by boiling for 5 minutes at 
95°C and the beads were removed using the magnet. For further identification, 
proteins were separated via SDS-PAGE and western blotting was performed. 
 
SDS-PAGE and Western Blot 
 
SDS-PAGE 
 
SDS Polyacrylamide Electrophoresis is a useful system to separate proteins 
according to their size. SDS is a powerful detergent, which has a very 
hydrophobic end (the lipid like dodecyl part) and highly charged part (the sulfate 
group). The dodecyl part interacts with hydrophobic amino acids in proteins. 
Since the 3D structure of most proteins depends on interactions between 
hydrophobic amino acids in their core, the detergent destroys 3D structures, 
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transforming what were globular proteins into linear molecules now coated with 
negatively charged SDS groups masking the actual charge of proteins. After 
boiling in SDS proteins therefore become elongated with negative charges 
arrayed down them, so they will move towards a positive electrode more or less 
fast according to their respective size. The reason why β-mercaptoethanol is 
usually included in the sample buffer is to cleave disulfide bonds within or 
between molecules, allowing molecules to adopt an extended monomeric form. 
Cell Lysates (f.i. the DAUDI cell line) or precipitated proteins or human IL35:Fc 
from Alexis Biochemicals (San Diego, CA - 1 µg/ml) were mixed with reducing 
Laemmli sample buffer (Biorad, Richmond, CA) containing 5% ß- 
mercaptoethanol (Biorad) and boiled before at 95 °C for 5 min. Proteins were 
separated by electrophoresis on 10% SDS-polyacrylamide gels using the 
Hoefer Mighty Small system (Amersham, Little Chalfont, UK). As running buffer 
25 mM Tris base, 192 mM glycine, 0,1% SDS was used. 
As protein standard SeeBlue Plus2 prestained marker (Invitrogen) was used. 
 
Polyacrylamid Gel preparation 
 
 
 
Western Blotting 
 
Western Blotting allows to determine, with a specific primary antibody, the 
relative amounts of the protein present in different samples. Separated samples 
Reagent 10% Separation gel 2% Stacking gel 
30% Acrylamide-solution 4 ml 440 µl 
H2O 4,8 ml 2 ml 
1,5 M Tris HCl pH 8,8 3 ml ----- 
0,5 M Tris HCl pH 6,8 ------ 840 µl 
10% SDS-solution 100 µl 35 µl 
Ammoniumpersulfate (10%) 100 µl 35 µl 
TEMED 
 
8 µl 4 µl 
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are transferred to a membrane for detection. The membrane is incubated with a 
generic protein to bind to any remaining sticky places on the membrane and 
therefore blocking unspecific antibody adherence on the membrane itself. A 
primary antibody is then added to the solution which is able to bind to its 
specific protein. A secondary antibody-enzyme conjugate, which recognizes the 
primary antibody is added to find locations where the primary antibody has 
bound. 
Proteins that were separated by SDS-PAGE were blotted onto Immobilon-P 
PVDF membranes (Millipore, Billerica, MA) using the Hoefer Semiphor TE77 
system (Amersham, Buckinghamshire, UK) for 1 hour at 15 V. As blotting buffer 
25 mM Tris base, 192 mM glycine, 5% Methanol was used. Membranes were 
blocked with 5% dry milk/0,1% Tween20 and incubated with primary antibody (1 
µg/ml) in the same solution. Bound mAbs were detected using HRP-conjugated 
goat antibodies to mouse Ig (used at 1:10.000; Dako) and chemiluminescence 
detection (Western Lightning; Perkin-Elmer, Wellesley, MA). Signals were 
detected on Kodak Biomax XAR films (Sigma-Aldrich) and quantified using the 
ImageJ 1.32 software (National Institutes of Health, Bethesda, MD). 
 
RNA-Isolation and cDNA preparation 
 
RNA was isolated using TRI reagent (Sigma-Aldrich, St. Louis, MO). Up to 1 x 
107 cells/ml were resuspended in 1 ml TRI reagent and incubated for 5 minutes 
(optional: -20°C until need) at room temperature. To remove protein 100 µl 
Chloroform were added, vortexed and incubated again for 5 minutes at room 
temperature. After centrifugation for 15 minutes at 13 000 rpm at 4°C the 
aqueous phase was transferred in new tube and 300 µl isopropanol were 
added. Samples were vortexed, incubated and centrifuged again at 13 000 rpm 
at 4°C for 10 minutes. The pellet was washed in 1 ml 75 % ethanol. The dried 
pellet was resuspended in A.dest (∼10 µl) and the concentration was measured 
at OD260. The ratio 260/280 should be over 1,5. 
2 µg of total RNA was reverse transcribed with MuLV
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Burlington, Canada) using Oligo (dT)18 primers, according to the 
manufacturer’s protocol. 2 µg RNA were mixed with 0,5 µg Oligo (dT)18 primers 
and A.dest was added up to 11 µl, incubated for 5 minutes at 70°C and chilled 
on ice. To each reaction 4 µl of 10 x M-MuLV reverse transcriptase buffer, 1mM 
4 dNTP mix, 20 U ribonuclease inhibitor, 200 U of RevertAid H Minus M-MuLV 
reverse transcriptase (all Fermentas) and A.dest to a final volume of 20 µl were 
added. The mixture was incubated for 5 minutes at 37°C, followed by incubation 
for 60 minutes at 42°C and 10 minutes at 70°C. Finally cDNA was diluted 1:3 to 
use it for qPCR. cDNA was stored at -20°C until use. 
 
Quantitative PCR (qPCR) 
 
Quantitative (Real–Time) PCR (qPCR) was performed by the Mx3005P QPCR 
system (Stratagene, Cedar Creek, TX) using SYBR Green I (Fermentas) 
detection according to the manufacturers protocol. In all assays, cDNA was 
amplified using a standard program (2 minutes at 50°C, 10 minutes at 95°C, 40 
cycles of 15 sec at 95°C / 15 sec at 60°C / 30 sec at 72°C). G3PDH was used 
as a housekeeping gene.  
 
The following primers were used:  
 
hFoxp3 forward:  5`-GAA ACA GCA CAT TCC CAG AGT TC-3`  
hFoxp3 reverse:  5`-ATG GCC CAG CGG ATG AG-3`  
 
hEBI3 forward:  5`-TCT GAG ATC TCT GCC CGC CCT GCA GTG GAA GG-3` 
hEBI3 reverse:  5`-CTT GAG ATC TGC CCA GGC TCA TTG TGG CAG TG-3` 
 
hIL-12 p35 forward: 5`-TTT GCG GCC GCA CCT CCC CGT GGC CAC TCC AG-3` 
hIL-12 p35 reverse:  5`-TTT GCG GCC GCA TTC AGA TAG CTC ATC ACT CT-3`  
 
hp28 forward:  5`-GCG GAA TCT CAC CTG CCA-3`  
hp28 reverse:  5`-GGA AAC ATC AGG GAG CTG CTC-3` 
Material and Methods 
IL-35+ regulatory T cells                                                                                                            Maria Seyerl 
98
 
G3PDH forward:  5`-CGACCACTTT GTCAAGCTCA-3`  
G3PDH reverse: 5`-AGGGGAGATT CAGTGTGGTG-3` 
 
Cell lines 
 
The following cell lines were used in this study: the EBV-transformed 
lymphoblastoid B cell line (EBV CL) OTMA was generated in our laboratory 
[182]. The Daudi cell line was obtained from American Type Culture Collection 
(ATCC, Manassas, VA). 
 
Statistical analysis 
 
Statistical analysis was performed using a 2-tailed Student's t test using 
unpaired nonparametric test (Mann-Whitney). Significance is represented as p 
< 0.05 (*), p < 0.01 (**) and p<0.001 (***), n.s. not significant. 
 
List of chemicals and reagents 
 
Reagent   final conc.  source 
Beriglobin 20 mg/ml (in PBS/BSA) Aventis Behring, Vienna, 
Austria 
PMA 100 nM Sigma, St. Louis, MO 
Ionomycin  1 µM Sigma, St. Louis, MO 
GM-CSF  
 
50 ng/ml 
Novartis Research Institute, 
Vienna 
IL-4 100U/ml 
Novartis Research Institute, 
Vienna 
Human IL35:Fc  
Alexis Biochemicals, San 
Diego, CA 
methyl-3H-thymidine  1mCi/ml Perkin Elmer, Waltham, MA 
Monensin 10 µM Sigma, St. Louis, MO 
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TRI Reagent (Trisol) undiluted Sigma, St. Louis, MO 
FIX Solution undiluted 
An der Grub, Kaumberg, 
Austria 
PERM Sulution undiluted 
An der Grub, Kaumberg, 
Austria 
IFN-α 5 ng/ml 
Boehringer Ingelheim Vienna, 
Austria 
IL-10 5 ng/ml 
R&D Systems Inc. 
Minneapolis, MN 
TGF-β 5 ng/ml 
R&D Systems Inc. 
Minneapolis, MN 
IL-12  
R&D Systems Inc. 
Minneapolis, MN 
WIN 52035 5 µg/ml 
Sterling-Winthrop Research 
Institute , Rensselaer, NY 
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Buffers and media 
 
Heparin media:  
Use 500 ml RPMI 1640 medium. Add 100 U/ml penicillin + 100 µg/ml 
streptamycin and 2mM L-glutamine (stored at –20°C, Sigma-Aldrich)). Add 10 
U/ml Heparin (stock: 5000 U/ml, Baxter, Vienna). 
 
Freezing medium: 
RPMI 1640 supplemented with 25% FCS and 10% DMSO  
 
MACS-buffer (stored at 0°C):  
1000 ml 1x PBS def. + 25 ml Human Serum Albumin (stock: 20%, Centeon, 
Vienna) + 10 ml EDTA (stock: 0,5 M); filtrated sterile 
 
10x PBS stock solution:  
5.8 g KH2PO4 16.6 g Na2HPO4 2H2O 72 g NaCl Solubilise the salts in 
aquabidest (=ddH2O), fill up to 10 litres and adjust pH to 7.2  
 
PBS/BSA stock solution (20%):  
100 g BSA 10 g NaN3 Dissolve in 500 ml PBS buffer.  
For the PBS/BSA wash buffer, prepare a 1:20 dilution with PBS buffer.  
 
Solutions for western blot:  
 
Running buffer (4x): 
Tris 12 g 
SDS 4 g 
Glycin 57,6 g 
up to 1000 ml ddH2O 
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Blotting Buffer:  
250ml of 4x running buffer  
200 ml methanol  
up to 1000 ml ddH2O 
Can be scaled down to 800 ml total volume.  
Degas before use!!!  
 
PBST (PBST 0.5%):  
PBS with 0.5 % Tween 20  
 
Dry milk solution  
5% dry milk powder dissolved in PBST buffer.  
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